忍者ブログ

ニュースリリースのリリースコンテナ第一倉庫

ニュースサイトなど宛てに広く配信された、ニュースリリース(プレスリリース)、 開示情報、IPO企業情報の備忘録。 大手サイトが順次削除するリリースバックナンバーも、蓄積・無料公開していきます。 ※リリース文中の固有名詞は、発表社等の商標、登録商標です。 ※リリース文はニュースサイト等マスコミ向けに広く公開されたものですが、著作権は発表社に帰属しています。

2025'03.15.Sat
×

[PR]上記の広告は3ヶ月以上新規記事投稿のないブログに表示されています。新しい記事を書く事で広告が消えます。

2007'02.01.Thu
International Breakthrough for Dutch Golf Simulator
February 16, 2006

-- Play at Pebble Beach and every golf course in the world without travelling -
    ZALTBOMMEL, Netherlands, Feb. 16 /Xinhua-PRNewswire/ --
The Dutch Golf Simulator is breaking through
internationally.  ProTee United, the producer of the
simulator, introduced two new models at the largest golf
fair in the world in Orlando, which took place earlier.
(See also: http://www.pgamerchandiseshow.com )
 
    "The response to our simulator was huge,"
Dennis van Drie, President of ProTee United, says.
"Our goal was attracting new sales outlets and
clients.  This goal has been amply met. The international
breakthrough of our simulator is now a fact." 

    The latest generation of simulators manufactured by the
Dutch producer are very advanced and realistic.  Users have
the possibility to play golf at any location they wish,
using a virtual driving range or an 18 hole golf course,
which includes bunkers, trees and water obstacles.  Using
the Simulator, everybody is able to play golf on every
course in the world, so people can actually play at courses
like Augusta, Pebble Beach or the K Club in Ireland, where
the Ryder Cup will take place this year. 
   
    "Our product has been tested by many professional
golfers and famous long hitters.  The longest drive was 385
yards, and reached a club speed of 156 miles per
hour."

    What is the secret of the success of this Dutch Golf
Simulator? "In Orlando, it appeared that we are
distinctive regarding price, graphical performance (3D
engine), modular structure (we use separate components,
which are obtainable in any length, width, height and
colour) and the quantity of sensor measuring
systems."

    ProTee will launch a couple of add-ons this year:
Vertical Sensors (which measure the Club head attack angle,
the ball launch angle etc.) and special putting sensors.

    New applications

    The ProTee Golf Simulator is composed from different
modules.  The basis of the system is completed with two
extra options, the `ball tracking sensor' and the `vertical
club head attack angle sensor'.  In addition, many,
graphically improved, golf courses have been added.  This
offers the possibility to use the simulator for swing
analysis at a club fitting.  A combination of three sensor
systems makes ProTee's simulator a unique product
worldwide. 

    NOTE TO EDITORS:  

    At http://www.protee-united.com/downloads , you can
find some visual material.

    For more information, please contact:

     Dennis van Drie
     President of ProTee United
     Tel:   +31-0418-654-950
     Email: dvdrie@protee-united.com
     Fax:   +31-0418-654-959

SOURCE  ProTee United B.V.


PR
2007'02.01.Thu
WHO Meeting Brings Together Leading Experts to Discuss Burden of Pneumococcal Disease
February 15, 2006

-- Prevention of Child Deaths Remains an Asian Priority 
-- Effective Surveillance is First Step to Eliminating
Disease 


    COLOMBO, Sri Lanka, Feb. 15 /Xinhua-PRNewswire/ -- The
need for an urgent and sustained effort to document the
burden of pneumococcal disease formed the core of
discussions amongst leading scientists attending a WHO
meeting today.  With pneumococcal disease estimated to be
responsible for up to one million child deaths each year(1)
-- local efforts to measure the scale of the problem in Asia
are essential in preventing unnecessary child deaths from
Streptococcus pneumoniae -- a bacterium that causes
pneumonia and meningitis.

    Serious pneumococcal infections occur throughout life,
but young children (especially those under 2 years old) and
the elderly are at the highest risk for severe pneumococcal
disease.  Furthermore, over 90% of pneumococcal pneumonia
deaths in children occur in developing countries, and
pneumococcal meningitis kills or disables over 40% of the
children who get the disease.

    "Effective surveillance of pneumococcal disease
and its serotypes is needed to accurately map the magnitude
of the problem and help evaluate the impact of available
vaccines", commented Dr Thomas Cherian, Co-ordinator
a.i., EPI+, Vaccines and Biologicals at WHO.

    Pneumococcal disease is a major global health problem,
and of concern in Asia.  For example, at the Lady Ridgeway
Hospital (LRH) for Children in Colombo, Sri Lanka -- one of
the largest Children's hospitals in the region -- 794
pneumonia cases (32 deaths) and 295 meningitis cases (9
deaths) were reported in 2003(2).  Pneumococcal
surveillance, initiated in 2005, indicates that a sizable
proportion of these cases could be due to infections by
Streptococcus pneumoniae. 

    Dr. Nihal Abeysinghe, the Chief Epidemiologist of the
Ministry of Health, is pleased that Sri Lanka is a part of
the South Asian Pneumococcal Alliance (SAPNA) and that
pneumococcal surveillance conducted in Sri Lanka is based
on sound methodology with high standards of quality
control.  He also emphasised the value and the importance
of technical and financial assistance by WHO and GAVI's
PneumoADIP in supporting and sustaining effective
pneumococcal surveillance activities in Sri Lanka. 

    Dr. Sarath de Silva, the Consultant Paediatrician at
the LRH said that the improved Microbiology Laboratory
support now provides clinicians with the opportunity to
identify pneumococci as a leading cause of meningitis and
pneumonia in children.  In 2005, Streptococcus pneumoniae
were isolated from specimens from 3 meningitis patients and
9 pneumonia patients. 

    Dr. Kumudu Karunarathne, the Consultant Microbiologist,
also at the LRH, commented that a high level of resistant
pneumococci to commonly used antibiotics was a very
significant finding in 2005.  The fact that over 90% of the
Streptococcus pneumoniae isolates are resistant to
penicillin is of greatest concern, and all clinicians in
the country should be aware of this fact.  

    Fortunately, new vaccines to prevent deadly
pneumococcal infections are now available and widely used
in many countries in North America and Europe.  As Dr.
Katharine O'Brien, Deputy Director for Surveillance and
Research at GAVI's PneumoADIP explained: "with
systematic surveillance in place and a coordinated effort
to introduce pneumococcal vaccines we could save millions
of children's lives and make a significant move towards
meeting a key UN Millennium Development Goal of reducing
child mortality by two thirds by 2015".

    The Pneumococcal Surveillance Investigators meeting was
sponsored by the World Health Organisation and GAVI's
PneumoADIP(3) and brought together experts from a number of
Asian countries including Bangladesh, India, Indonesia,
Republic of Korea, Mongolia, Nepal, Sri Lanka, Thailand and
Viet Nam.

    The importance placed on this meeting reflects the
global community's increasing focus on pneumococcal
disease, and the urgent need for a global solution.  Only
last week BBC World aired the second in a landmark series
of programmes looking at pneumococcal disease and
life-saving vaccines.  The documentary took a close look at
the burden of pneumococcal disease in India and Nepal, and
the effort required to introduce a vaccine in developing
countries.

    Notes to Editors

    Pneumococcal Disease

    Pneumococcal disease is an infection caused by
Streptococcus pneumoniae. When these bacteria invade the
lungs, they cause the most common kind of bacterial
pneumonia and can then invade the bloodstream (bacteremia)
and/or the tissues and fluids surrounding the brain and
spinal cord (meningitis). 

    According to WHO, pneumococcal pneumonia and meningitis
are responsible for 800,000 to 1 million child deaths each
year and more than 90 percent of pneumococcal pneumonia
deaths in children occur in developing countries. 
Furthermore, approximately 500,000 children die each year
from diarrhoeal disease caused by rotavirus, and another 2
million are hospitalized.  Since rotavirus diarrhoea is a
global infection, nearly every child in the world will
suffer an episode of diarrhoea caused by rotavirus before 5
years of age.

    South Asian Pneumococcal Alliance (SAPNA)

    Sri Lanka became a member of the SAPNA in 2003 and
started Laboratory based surveillance of pneumococcal
infections in 2005 at the Lady Ridgeway Hospital for
Children in Colombo.  The Epidemiology Unit of the Ministry
of Health coordinates the surveillance activities.  It plans
to expand surveillance activities to cover the whole Colombo
district.

    World Health Organisation (WHO)

    The World Health Organization is the United Nations
specialized agency for health.  It was established on 7
April 1948. WHO's objective, as set out in its
Constitution, is the attainment by all peoples of the
highest possible level of health.  Health is defined in
WHO's Constitution as a state of complete physical, mental
and social well-being and not merely the absence of disease
or infirmity.

    Pneumococcal Vaccines Accelerated Development and
Introduction Plan (PneumoADIP)

    The goal of PneumoADIP is to shorten the time between
the use of a new vaccine in industrialized countries and
its introduction in developing countries by reducing demand
uncertainty and achieving an affordable, sustainable supply
of vaccines.  This novel approach is funded by the Global
Alliance for Vaccines and Immunization (GAVI) through its
partner the Vaccine Fund.  PneumoADIP is located at the
Johns Hopkins Bloomberg School of Public Health.  The
mission of PneumoADIP is to improve child survival and
health by accelerating the evaluation of and access to new
life saving pneumococcal vaccines for the world's children.
 For more information, please visit:
http://www.preventpneumo.org .

    GAVI Alliance  

    The Global Alliance for Vaccines and Immunization (now
the GAVI Alliance) was launched in 2000 to increase
immunization rates and reverse widening global disparities
in access to vaccines.  Governments in industrialized and
developing countries, UNICEF, WHO, the World Bank,
non-governmental organizations, foundations, vaccine
manufacturers, and public health and research institutions
work together as partners in the Alliance, to achieve
common immunization goals, in the recognition that only
through a strong and united effort can much higher levels
of support for global immunization be generated.  Funds
channeled through GAVI's financing arm, The GAVI Fund
(formerly The Vaccine Fund), are used to help strengthen
health and immunization services, accelerate access to
selected vaccines and new vaccine technologies --
especially vaccines that are new or under-used, and improve
injection safety.  In addition to substantial funding from
the Bill & Melinda Gates Foundation, The Vaccine Fund
has been financed by ten governments to date-Canada,
Denmark, France, Ireland, Luxembourg, the Netherlands,
Norway, Sweden, the United Kingdom, and the United States-
as well as the European Union and private contributors.

    (1) World Health Organization. Pneumococcal vaccines.
The Weekly Epidemiol 
        Record 2003;14:110-9

    (2) Annual Health Bulletin, LRH, 2003
 
    (3) Pneumococcal Vaccines Accelerated Development and
Introduction Plan 
        (PneumoADIP) based at Johns Hopkins Bloomberg
School of Public Health, 
        USA

    For more information, please contact:

     Hans Kvist, Director, Communications,
     GAVI's PneumoADIP 
     Tel:   +1-410-736-8243
     Email: hkvist@jhsph.edu

     Selina Haylock, Consultant,
     Ruder Finn Communications
     Tel:   +44-776-882-3989
     Email: shaylock@ruderfinn.co.uk

     Dr. Ranjith Batuwanthudawe, Principal Investigator,
     SAPNA Sri Lanka Project, 
     Epidemiology Unit, Ministry of Health
     Tel:   +94-112-695112
     Email: chepid@sltnet.lk 

SOURCE  GAVI's PneumoADIP
2007'02.01.Thu
SEVEN Marks Record Growth Reaching Sales of Over One Million Mobile Push Email Licenses
February 15, 2006

With 80 Mobile Operator Customers in Over 45 Countries, SEVEN Is Positioned as the 2nd Largest Mobile Email Provider
    BARCELONA, Spain, Feb. 15 /Xinhua-PRNewswire/ -- SEVEN
today announced that it has sold over 1 million licenses of
its push email software of which approximately 75% are
enterprise licenses and 25% are individual prosumer and
consumer licenses.  Over 80 mobile operators and service
providers have selected SEVEN as their white-label push
email solution.  SEVEN's customers include some of the
largest mobile operators in the world including Cingular
offering XpressMail; KDDI offering Keitai Office; and
Telefonica offering Mail Movistar -- all powered by SEVEN's
push email software. 

    SEVEN is the second largest provider of mobile email
after market-leader Research in Motion as measured by the
following leadership attributes: 

    All information provided in the following table was
sourced from the noted company's website as of February 14,
2006 as detailed in the footnotes.


                 RIM          SEVEN  Intellisync Visto   
Good
    Mobile  
     Operator 
     Customers  150(1)        80(2)     19(3)    16(4)   
2(5)
    Devices  
     Supported  21+10(6)      120(7)    50(8)    75(9)   
16(10)
    Device OS  
     Support    Proprietary   5 Brew;   4(11)    4(12)   
3(13)
                              Java;     Brew;    Symbian,
Palm,
                              Palm,     Palm,    Palm,   
Windows,	
                              Symbian,  Symbian  Windows 
Symbian	
                              Windows   Windows  Mobile,	
                              5.0       5.0      Java
    Email Systems   
     Supported  5             5         4(14)    4(15)   
1(16)
                Exchange,     Exchange,
Exchange,Exchange,Exchange
                Domino,       Domino,   Domino,  Domino,
                Groupwise,    Groupwise,POP3,    POP3,
                POP3,         POP3,     IMAP     IMAP
                IMAP          IMAP
    Ranking     #1            #2        #3       #4      
#5


    One Million Licenses Sold -- Only One Indicator of
Growth 

    Surpassing sales of over 1M licenses is only one
indication of SEVEN's growth rate as many of our customers
buy licenses as they are "consumed" and not in
advance -- at a pace that varies by market and by how long
the SEVEN-powered service has been in market.  In Japan,
SEVEN has seen substantial growth in large-scale enterprise
adoption and, for example, is currently deploying two large
deployments of 10,000 and 8,000 licenses respectively. 
These are "pay as consumed" contracts and are
additive to SEVEN's total license base.  SEVEN believes the
total market for push email will reach over one quarter
billion subscribers within five years as push email becomes
widely available as a standard feature across all mobile
handsets. 

    Customer Expansion to 80 Operators Includes High-Growth
Markets

    SEVEN also has seen phenomenal growth in many
high-growth markets such as India, the Middle East and
South America.  In India, SEVEN works with IDEA and
Hutchison and has recently signed deals with two regional
operators that are yet announced. In the Middle East, SEVEN
works with MTC Vodafone Group, Wataniya, Batelco and
Etisalat Group.  In South America, SEVEN works with
Telefonica across 14 properties and 15 countries. 

    "SEVEN has been heads-down developing innovative
technology to grow mobile email adoption.  We want mobile
email to work on every phone without hassle and major
expense -- whether you are an enterprise or consumer,"
said Kent Thexton, President and CEO of SEVEN.  "It is
gratifying to see our progress against that goal -- while
the market is still early in realizing its potential, we
have built a solid foundation based on innovation that will
cement our leadership position in the long term." 

    NOTE:  SEVEN is a registered trademark of Seven
Networks, Inc.  Out of the Office, System SEVEN, SEVEN
Personal Edition, SEVEN Enterprise Edition, and SEVEN
Server Edition are also trademarks or service marks of
Seven Networks, Inc.  All other trademarks or tradenames
are those of their respective owners.

    1) 3GSM World Congress February 14 2006; Presentation
Title: Service        Architecture to Drive Productivity;
Speaker: Jim Balsillie, Chairman &        Co-Chief
Executive Officer, Research in Motion

    2) http://www.seven.com/get_it/

    3)
http://www.intellisync.com/pages/Customers/Mobile-Carriers/
  
    4) http://www.visto.com/partners/wireless.html 

    5) http://www.good.com/index.php/how_to_buy.html
  
    6) http://www.rim.com/products/handhelds/index.shtml
(21 Blackberry        
       devices, 10 from other manufactures / Blackberry
Connect)

    7) http://www.seven.com/products/devices/index.html

    8) http://www.intellisync.com (This is an estimated
number based on the      
       data gathered from different sources on the web
site)

    9) http://www.visto.com/news/press_kit.html (Fact
Sheet)

    10)
http://www.good.com/index.php/products-software.html

    11)
www.intellisync.com/pages/products/email-accelerator  

    12) http://www.visto.com (About) 

    13)
http://www.good.com/index.php/products-software.html 

    14)
www.intellisync.com/pages/products/email-accelerator 

    15) http://www.avisto.com (About) 

    16)
http://www.good.com/index.php/products-software.html

    For more information, please contact:

     Kate O'Sullivan
     Tel:   +1-415-307-3148
     Email: kate.osullivan@seven.com

     Arlinda Sipila
     Tel:   +358-40-528-8651
     Email: arlinda.sipila@seven.com

SOURCE  SEVEN
2007'02.01.Thu
Australia's CASA Grants Procedure Design Certificate to Naverus
February 15, 2006

Naverus Criteria Judged to Provide Substantially Increased Safety;
Approval Will Accelerate Enhancements to Australian Airspace
    RENTON, Wash., Feb. 15 /Xinhua-PRNewswire/ --
Australia's Civil Aviation Safety Authority [CASA] has
granted an Instrument Flight Procedure Design Certificate
to Naverus, Inc., authorizing them to design and maintain
Required Navigation [RNP RNAV] approach and departure
procedures for the Australian airspace.  The certification
-- the first granted to an entity not affiliated with the
government, and the only certification permitting the
design of RNP-AR (Authorization Required) procedures --
will accelerate the deployment of performance-based
navigation procedures, and enhance the safety as well as
the efficiency of airlines serving airports in Australia.

    Bruce Gemmell, the Deputy Chief Executive and Chief
Operating Officer of CASA, certified Naverus under Part 173
of the Civil Aviation Safety Regulations 1998.  The
certification follows a rigorous review of Naverus'
operations, and consultation with Transport Canada, the FAA
and the CAA of New Zealand about the safety aspects of the
Naverus design criteria.  The review included an
independent, on-site audit of the Naverus design offices in
Seattle, WA by CASA's Sophie Joshua and Paul Taylor.  The
CASA team inspected the processes and quality management
plan that Naverus has developed through its design of over
250 RNP approach, departure and enroute procedures,
including procedures designed for Australian and New
Zealand airports.  Gemmell noted in his decision that the
Naverus design criteria "provide substantially
increased safety over procedures designed using
conventional criteria of the kind found in ICAO Doc. 8168
(PANS-OPS)" and, while consistent with the FAA and
proposed ICAO criteria for RNP, "incorporates several
features which permit additional safety and operational
benefits" beyond those criteria. 

    Dan Gerrity, Naverus' Chief Executive Officer,
appreciated the rigor of CASA's review.  "CASA has set
the bar very high for this certification, as it
should," observed Gerrity.  "Australia's process
gives other regulators around the world a strong model to
follow as our industry moves to capture the benefits of
performance-based navigation using RNP."  CASA has
also approved the appointment as chief designer of Naverus'
Michael Ryan and Mark Brower, who lead the team of design
engineers, performance engineers, and navigation data
experts who to-date have designed and released hundreds of

performance-based navigation procedures to multiple
criteria for operators worldwide.

    The approval by CASA for Australia is the second
granted to Naverus by a major regulatory agency.  In 2004,
Transport Canada granted Naverus a delegation to design,
publish and maintain RNP RNAV procedures for Canada, under
an exemption to that agency's CAR 803.02.  Transport Canada
renewed that grant in July, 2005. 

    About Naverus 

    Naverus is the leader in performance-based navigation
solutions to airlines and airports worldwide.  Naverus has
developed and deployed over 250 RNP RNAV procedures for
both Boeing and Airbus aircraft.  Customers include
JetBlue, Air New Zealand, Qantas and WestJet.  The Seattle
company was founded in 2003 by the industry's most
experienced performance-based navigation experts.  Based in
Renton, WA, the company is a privately-held corporation. 
Investors include JGE Capital Management, other private
equity groups and individuals.  For more information,
please visit http://www.naverus.com or call Naverus at
1-425-282-5250.

    About CASA

    The Civil Aviation Safety Authority (CASA) was
established on 6 July 1995 as an independent statutory
authority.  CASA's primary function is to conduct the
safety regulation of civil air operations in Australia and
the operation of Australian aircraft overseas. 

    The Civil Aviation Act and CAR 1988 empower CASA to
issue Civil Aviation Orders on detailed matters of
regulation.  The Chief Executive Officer manages CASA, and
is responsible to the Minister for Transport and Regional
Services.

    For more information, please contact:

     Stew Chapin,
     Naverus Marketing
     Tel:   +1-425-282-5267
     Email: schapin@naverus.com

SOURCE  Naverus, Inc.
2007'02.01.Thu
Esselte Enters Equity and Licensing Agreement With Swedish Technology Company PrintDreams
February 15, 2006

Strategic Partnership Sets the Stage for Groundbreaking New Product
Development Initiatives for Creative and Business Consumers
    STAMFORD, Conn. and STOCKHOLM, Sweden, Feb. 15
/Xinhua-PRNewswire/ -- Esselte, a leading global office
supplies company, has announced a strategic partnership
with the Swedish company PrintDreams.  PrintDreams
developed the RMPT(TM) Lite (Random Movement Print
Technology) used in the newest product introduction from
Xyron, part of Esselte's Creative Division.  The Xyron(R)
Design Runner(TM), a first-of-its-kind, cordless,
hand-held, portable digital printer, was introduced in
October 2005 and represents the first commercial
application for RMPT Lite since its inception in 2003.

    The Esselte-PrintDreams partnership includes a minority
equity position for Esselte in PrintDreams as well as a
license agreement for the RMPT Full technology, which will
be used in the development of innovative new products for
Xyron and Esselte's office supply brands, Pendaflex(R) and
Leitz(R).  Financial terms of the partnership were not
released.

    "This collaboration with PrintDreams is an
extension of Esselte's commitment to identifying and
securing innovative, ground-breaking technologies,"
commented Gary Brooks, president and CEO of Esselte. 
"With each new product introduction -- for our office,
home office, craft, hobby, art and education markets -- we
look to simplify complicated, cumbersome processes and make
the consumer more productive.  With go-forward partners like
PrintDreams we are sure to reach new heights in these
areas."

    The partnership will extend and expand upon the
successful introduction of the Xyron Design Runner.  This
revolutionary portable printer is the first and only print
device on the market that allows users to add printed
elements to virtually any project, without wires, computer
connections or an electric power source.  The
battery-operated Xyron Design Runner can print on nearly
any substrate as well -- paper, fabric, ribbon, clay, and
myriad other surfaces -- and uses a series of proprietary
Design Discs that offer image, WordArt, texture and
alphabet options.

    "Our vision at PrintDreams' is to establish a
global de facto standard for truly portable printer
devices," stated Alex Breton, chairman and CEO of
PrintDreams.  "RMPT technology is the foundation that
will allow us to do just that.  And with partners like
Esselte we are sure to expand on the success of the Xyron
Design Runner and provide real-time, portable printing
solutions to consumers in a variety of markets."

    Esselte expects to introduce new and innovative digital
printing products incorporating the RMPT Full technology
beginning in late 2006 and early 2007. 

    About PrintDreams

    PrintDreams is a Swedish high technology company that
develops, markets and sells license rights for innovative
technical solutions, primarily for the printer industry. 
The company has developed among others, RMPT(TM), which
allows the manufacturing of truly portable printer devices
suitable for mobile applications.  Another advantage of
RMPT (Random Movement Printing technology) is that it is
highly flexible; allowing printing on almost any type, size
or format of surface.  Additionally it is very cost
effective because the hundreds of mechanical parts common
in traditional printers are replaced by an intelligent
software-based control system.  PrintDreams has also
developed the world's foremost accurate optical navigation
sensor called OptoNav(TM).  This sensor has applications in
more advanced printer products that the company is currently
developing together with its partners.  To get to know more
about the company and its technologies please visit
http://www.printdreams.com .

    About Esselte

    Esselte, with executive offices in Stamford, Conn.,
USA, is a leading global office supplies manufacturer with
annual sales of approximately USD 1 billion, subsidiaries
in 33 countries and approximately 5,000 employees
worldwide.  The company develops innovative solutions that
simplify the modern home and workplace.  Esselte sells more
than 20,000 different office products in over 120 countries;
its principal brands include Esselte, Leitz, Oxford(R),
Pendaflex and Xyron. More information about Esselte can be
found by visiting http://www.esselte.com .

    For more information, please contact:

     Amy Romano
     Tel:   +1-480-607-6333
     Email: a.romano@xyron.com

SOURCE  Esselte; PrintDreams
2007'02.01.Thu
InterContinental Hotels Group signs 4,500 rooms in landmark China deal
February 15, 2006

Deal involves six hotels in Sichuan province
Further strengthens Group's market leadership in China
    CHENGDU, China, Feb. 15 /Xinhua-PRNewswire/ --
InterContinental Hotels Group, the world's largest hotel
group by number of rooms, today signed a landmark deal with
Chengdu International Exhibition & Convention Group to
manage six hotels in Chengdu and Jiuzhaigou in China's
Sichuan province.  This deal significant enhances the
group's market dominance in China.  The six hotels -- two
InterContinental properties, three Holiday Inn properties
and one Express by Holiday Inn -- comprise a total of more
than 4,500 rooms.

    This landmark signing in Sichuan, China's second most
populous province with over 90 million residents, marks a
significant addition to InterContinental Hotels Group's
already strong portfolio of about 50 hotels in Greater
China.  It puts the Group in a strong position to reach its
target of having 125 hotels open in China by 2008.

    Chengdu, the strategically-located capital of Sichuan
province, is both an emerging powerhouse and a popular
tourism destination.  It is a fast-developing city that has
been named as one of the most livable cities China in and is
one of the top-ranked cities for tourism and economic
potential. 

    The Jiuzhaigou Scenic Area, a 45-minute flight from
Chengdu, is known for its pristine beauty, with emerald
lakes, layered waterfalls, colourful forests, snow peaks
and Tibetan folk villages.  The area is listed as a UNESCO
(United Nations Educational, Scientific and Cultural
Organization) World Natural Heritage site.   

    Andrew Cosslett, Chief Executive, IHG, who was in
Chengdu for the signing, said: "This is the biggest
single deal IHG has done in China, a country that lies at
the heart of our growth strategy.  Our brands have a strong
foothold in Asia Pacific and Holiday Inn was one of the
first international hotel brands to establish a presence
there in 1984.  This deal marks a major milestone as we
move towards meeting our aggressive growth plans and we
remain fully committed to maintaining our position as the
leading hotel company in China." 

    Edmond Ip, InterContinental Hotels Group's chief
operating officer for North Asia, said: "This latest
deal is concrete proof that InterContinental Hotels Group
is indeed the hotel partner of choice.  Our growing
portfolio clearly demonstrates that our partners recognise
the value of our award-winning brands and have complete
confidence in our ability to deliver memorable guest
experiences coupled with exceptional business
performance."

    "We are pleased to cooperate with an experienced,
international hotel operator like the InterContinental
Hotels Group on this significant project.  Our partnership
with InterContinental Hotels Group combines their
world-recognized hotel brands and established operating
systems with our local market knowledge and property
portfolio.  We believe that this cooperation will also
contribute to bringing Chengdu and Western China into
sharper focus with the international business
community," commented Deng Hong, Chairman of Chengdu
Exhibition & Convention Group. 

    The scheduled openings will comprise the following
hotels:

    In Chengdu City, as part of the RMB 5 billion (US$620
million) New Century City international convention and
exhibition centre, incorporating shopping, entertainment,
offices, residences and a golf course:

    InterContinental Century City Chengdu, an upscale
business hotel that will combine the latest communication
and business technologies, high-end food and beverage
options and conference facilities.  Scheduled to open in
2007.

    The two Holiday Inn hotels at the Chengdu Century City
New Convention & Exhibition Center are mid-scale hotels
offering quality accommodation and business support
services, specifically designed to host convention
delegates.  Scheduled to open in 2006.

    At the Jiuzhaigou Scenic Area, as part of Jiuzhai
Paradise, hailed as the `Davos of China':

    InterContinental Resort Jiuzhai Paradise, an upscale
hotel with eight F&B outlets and extensive conference
and recreational facilities.  Scheduled to open in 2006.

    Holiday Inn Jiuzhai Jarpo, a mid-scale hotel business
services and spa facilities.  Scheduled to open in 2006.

    Express by Holiday Inn Jiuzhai Jarpo, a
convenience-sector hotel scheduled to open in 2007.

    Chengdu International Exhibition & Convention Group
has interests in exhibitions and conventions, hotels, travel
agencies and real estate.  The Group commands more than 70%
market share for exhibitions and conventions in Chengdu and
had total revenues of RMB2.2 billion (US$265 million) in
2005.  The first stage of the New Century City project in
Chengdu is scheduled for completion by end of 2006. 

    Note to Editors

    InterContinental Hotels Group PLC of the United Kingdom
[LON: IHG, NYSE: IHG (ADRs)] is the world's largest hotel
group by number of rooms.  InterContinental Hotels Group
owns, manages, leases or franchises, through various
subsidiaries, almost 3,600 hotels and 539,000 guest rooms
in nearly 100 countries and territories around the world. 
The Group owns a portfolio of well recognised and respected
hotel brands including InterContinental(R) Hotels &
Resorts, Crowne Plaza(R) Hotels & Resorts, Holiday
Inn(R) Hotels and Resorts, Holiday Inn Express(R),
Staybridge Suites(R), Candlewood Suites(R) and Hotel
IndigoTM, and also manages the world's largest hotel
loyalty programme, Priority Club(R) Rewards.

    Asia Pacific is the fastest growing region for
InterContinental Hotels Group worldwide.  The Group's
portfolio in this region includes more than 160 hotels and
over 44,000 guest rooms under the InterContinental(R)
Hotels & Resorts, Crowne Plaza(R) Hotels & Resorts,
Holiday Inn(R) Hotels and Resorts, and Express by Holiday
Inn(R) brands.

    InterContinental Hotels Group offers information and
online reservations for all its hotel brands at
http://www.ichotelsgroup.com and information for the
Priority Club Rewards programme at
http://www.priorityclub.com .

    For the latest news from InterContinental Hotels Group,
visit our online Press Office at http://www.ihgplc.com/media
.

    For further press information and photos, please
contact:

     Sharona Tao
     Brand Public Relations & Communications Manager,
Greater China
     InterContinental Hotels Group
     Tel:   +86-21-2893-3309
     Fax:   +86-21-2893-3399
     Email: sharona.tao@ichotelsgroup.com

SOURCE  InterContinental Hotels Group
2007'02.01.Thu
Shanghai Petrochem Science and Technology Museum Formally Opens in Jinshan District
February 15, 2006

            
    SHANGHAI, China, Feb. 15 /Xinhua-PRNewswire/ --
Shanghai Jinshan District Government announces that the
first Petrochem Museum in China, Shanghai Petrochem Science
and Technology Museum, formally opened recently in Jinshan
District, Shanghai.  That brings the total of specialized
Science and Technology Museums in Shanghai to 17.

    Shanghai Petrochem Science and Technology Museum covers
an area of 1,500 square meters, built under the joint
investment of Shanghai Science and Technology Committee and
SINOPEC Shanghai Petrochemical Co., Ltd. (SPC) and based on
the original SPC Exhibition Hall.  By adding more
exhibitions and through using modern technology, the
original SPC Exhibition Hall was transformed into the
Shanghai Petrochem Science and Technology Museum.

    About Jinshan District

    Jinshan, one of the 19 districts (counties) of
Shanghai, is located in the southwest of the city, north of
the Hangzhou Bay and west of Zhejiang Province.  It is
situated at the hub of the economic region linking
Shanghai, Hangzhou and Ningbo, and is inside the geographic
ring of the Yangtze River Delta that is only a two hours
drive away.  

    Jinshan District has a total land area of 586 square
kilometers (about 226 square miles), equivalent to that of
Singapore, and a population of 550,000.  It has rich
natural and cultural heritages, including beautiful beach
lines, famous traditional peasant paintings, black ceramic
arts and crafts, and a world-renowned petrochemical base.

    For more information, please contact:

     Wang Ren of Shanghai Jinshan District Government
     Tel:   +86-21-5792-1325
     Fax:   +86-21-5792-1100
     Email: jsqzhk@sohu.com

SOURCE  General Office of the People's Government of
Jinshan
2007'02.01.Thu
SEVEN launches Mobile Email Solution for Small Businesses and Workgroups for up to 25 people
February 14, 2006

SEVEN Workgroup Edition* Removes Technical and Economic Barriers Impeding Broad Deployment of Mobile Email in the SME market
    BARCELONA, Spain, Feb. 14 /Xinhua-PRNewswire/ -- Today
at the 3GSM World Congress, SEVEN announced the
availability of its Workgroup Edition software extending
the benefits of push-email to small businesses and
departments within enterprises.  SEVEN Workgroup Edition
provides up to 25 users access to email, calendar,
attachments and contacts on a wide range of mobile devices.
 Installation of the software typically takes less than 15
minutes and involves a simple download to a single computer
connected to a corporate network -- no IT expertise is
required.  SEVEN's Workgroup Edition software was designed
with the highest enterprise-class security: all the data
associated with SEVEN's push-email client is secured by
end-to-end 128-bit AES encryption and SEVEN's software
comes rich with features such as remote data removal if a
device is lost.  SEVEN Workgroup Edition enables mobile
access to email that originates in Microsoft Outlook, Lotus
Domino, POP3-and IMAP-4 compliant email servers and allows
users to access more than one email account (e.g. personal
and work email accounts) through the same software at no
additional charge.

    SEVEN Workgroup Edition is currently being deployed and
offered through mobile operators and resellers worldwide. 
Mobile operators already offering SEVEN's Workgroup Edition
include StarHub in Singapore offering StarHub Duality,
Telemar in Brazil offering E-Mail Movel, and Pannon in
Hungary offering Pannon E-Phone.  In some markets, it is
also offered as Ericsson Mobile Organizer from Ericsson. 
The cost to use SEVEN Workgroup Edition will vary from
market to market, but as a general guideline it is
typically offered for below 10 Euros per month per
subscriber making it a very affordable productivity tool
for businesses of all sizes.  For a complete list of the 80
operators offering SEVEN software and their associated
service fees, please visit http://www.seven.com/get_it and
for companies and individuals interested in requesting a
free trial, please visit:
http://www.seven.com/get_it/info_request_form.html . 

    * SEVEN is a registered trademark of Seven Networks,
Inc. Out of the Office, System SEVEN, SEVEN Personal
Edition, SEVEN Enterprise Edition, and SEVEN Server Edition
are also trademarks or service marks of Seven Networks, Inc.
All other trademarks or tradenames are those of their
respective owners.

    North America & Japan
     Kate O'Sullivan
     Tel:   +1-415-307-3148
     Email: kate.osullivan@seven.com

    EMEA & APAC
     Arlinda Sipila
     Tel:   +358-40-528-8651
     Email: arlinda.sipila@seven

SOURCE  SEVEN 
2007'02.01.Thu
Xinhua Finance Achieves Full Year Profitability
February 14, 2006

Record Revenue, EBITDA and Net Income Exceed Forecasts for the Full Year 2005
    SHANGHAI, China, Feb. 14 /Xinhua-PRNewswire/ -- Xinhua
Finance (TSE Mothers: 9399; OTC ADR: XHFNY), China's
unchallenged leader in financial information and media,
today reported net income of US$10.3 million for the full
year 2005 under International Financial Reporting Standards
("IFRS").  Net income was significantly ahead of
the full year forecast, which was revised upward in
December 2005 to US$9.0 million.  The company has continued
to see significant growth across its global service lines. 
The record financial results for the full year are further
evidence that management's focused strategy for profitable
growth is driving shareholder value and that Xinhua Finance
is well-positioned to capitalize on its promising business
prospects in China and worldwide. 

    Total revenue for the full year ended December 31, 2005
was US$110.0 million, an 84% increase over the full year
2004, surpassing the forecast of US$105.7 million by US$4.3
million or 4%.  EBITDA, an important international measure
of high growth companies such as Xinhua Finance, was
US$21.2 million, a 364% increase from prior year EBITDA of
US$4.6 million, beating the US$16.7 million forecast by
27%.

    Fredy Bush, CEO of Xinhua Finance, commented, "We
are proud to have surpassed our full year revenue and
EBITDA targets to deliver net income significantly ahead of
expectations.  Fiscal 2005 was a landmark year for Xinhua
Finance, both financially and operationally.  Continued
strong demand for our China products as well as positive
developments in China's regulatory environment drove growth
across all of our business lines.  We have seamlessly
integrated our recent acquisitions into the group, and they
already are strengthening our product portfolio and
contributing to bottom line profit." 

    "Looking forward to 2006, we expect to continue to
advance our strategy to extend our distribution capabilities
in China and penetrate the financial media sector.  Our core
businesses continue to grow.  By improving the quality and
depth of our proprietary content, we are creating
additional leverage to develop these financial media
distribution channels and diversify into new and lucrative
revenue streams." 

    CFO Gordon Lau added, "Xinhua Finance achieved
record financial performance in fiscal 2005.  Revenue,
EBITDA and net income were at all time highs, a direct
result of our disciplined approach to expand our margins
and drive operational efficiencies.  EBITDA margin for the
full year 2005 more than doubled from 7% in fiscal 2004. 
Given our continued strong performance and the robust
demand for our China products, we are confident in
achieving our full year 2006 forecasts."


    Full Year 2005 results vs. forecasts - unit: million
USD

                          2005 forecast       2005 actual  
     % change     
    Revenue                       105.7             110.0  
          4 %
    EBITDA                         16.7             
21.2(1)         27 %
    Net Income                      9.0              10.3  
         14 %


    Full Year 2006 forecasts - unit: million USD
 
                           For 6 months      For the year  
  
    Revenue                        74.7             166.0 
    EBITDA                         11.5              25.6 
    Net Income                      6.4              13.8 


    Full Year 2005 results (Japan GAAP(2)) - unit: million
USD
 
                            2005 actual           
    Revenue                       110.0 
    EBITDA                         18.8(1)
    Net Income (loss)(3)           (2.8)
                            
                                   
     (1) For FY2005 IFRS Reported EBITDA of US$21.2 mn and
Japan GAAP Reported 
         EBITDA of US$18.8 mn, the difference includes
US$1.5 mn of one-time forex 
         and sale of non-core assets gains, and US$0.9 mn
of other GAAP 
         reconciliatory items.
     (2) The main reason for the discrepancy between IFRS
and Japan GAAP is that  
         Japanese accounting standards take a different
approach to accounting for 
         goodwill from acquisitions.
     (3) Includes one-time charges of USD$4.4 million
associated with fundraising 
         activities.

    (Notes)

     A. We define EBITDA in relation to our IFRS financial
statements as profit 
        (loss) before interest, tax, depreciation and
amortization.
     B. Forecasts for fiscal 2006 are management estimates
only; figures have not 
        been audited or reviewed. 
     C. Performance estimates are determined based on
information currently 
        available.  Due to unforeseen factors, actual
performance may differ from 
        estimates.

    About Xinhua Finance Limited

    Xinhua Finance Limited is China's unchallenged leader
in financial information and media, and is listed on the
Mothers board of the Tokyo Stock Exchange (symbol: 9399)
(OTC ADRs: XHFNY).  Bridging China's financial markets and
the world, Xinhua Finance serves financial institutions,
corporations and re-distributors through four focused and
complementary service lines: Indices, Ratings, Financial
News and Investor Relations.  Founded in November 1999, the
Company is headquartered in Shanghai with 18 offices and 21
news bureaus across Asia, Australia, North America and
Europe. 

    For more information, please visit
http://www.xinhuafinance.com . 

    For more information, please contact:

    Xinhua Finance
     
    Japan
     Mr Sun Jiong
     Tel:   +81-3-3500-5328
     Email: jsun@xinhuafinance.com
     
    China
     Ms Joy Tsang 
     Tel:   +86-21-6113-5999, +86-136-2179-1577,
+852-3196-3983, +852-9486-4364    
     Email: joy.tsang@xinhuafinance.com 

    Taylor Rafferty (IR Contact)

    Japan
     Mr. James Hawrylak 
     Tel:   +81-3-5733-2621 
     Email: james.hawrylak@taylor-rafferty.com

    United States
     Mr. Brian Rafferty
     Tel:   +1-212-889-4350
     Email: xinhuafinance@taylor-rafferty.com

SOURCE  Xinhua Finance Limited
2007'02.01.Thu
JBlend(TM) to be Demonstrated on Freescale 3G Platform with NVIDIA at 3GSM World Congress 2006
February 14, 2006

Visit Freescale Semiconductor Booth, #B37
    BARCELONA, Spain, Feb. 14 /Xinhua-PRNewswire/ -- Aplix
Corporation (TSE: 3727) announced today that they are
collaborating on a platform to feature their JBlend(TM)
Java(TM) technology running on Freescale's ARM11 processor
with an optional NVIDIA graphics processing unit (GPU). 
These chipsets, when combined with the JBlend platform,
result in a leading-edge demonstration, showcasing the
depth and breadth of Java on mobile devices.

    At the heart of the demonstration is Freescale's
i.MX31L multimedia applications processor.  The i.MX31L
features an ARM11(TM) processor core, designed to deliver
high fidelity audio, as well as video playback, capture and
conferencing for a stunning multimedia experience.  The
NVIDIA(R) GoForce(R) 5500 handheld graphics processing unit
(GPU) compliments the i.MX31L multimedia capabilities
maximizing the user experience for graphical Java
applications, such as those using the Mobile 3D API
(JSR-184).  The ARM11 processor core is also at the heart
of the Freescale's Mobile eXtreme Convergence MXC300-30 3G
platform.

    "Our customers have come to know Aplix as the
worldwide leader for Java on mobile phones," said
Wesley Kuo, President and Chief Strategy Officer of Aplix
Corporation.  "Aplix continues this trend by
constantly supporting new processor technologies, as
highlighted in this exciting demonstration.  We are very
encouraged by our recent cooperation with Freescale and
NVIDIA.  Our partnerships with Freescale and NVIDIA enable
us to integrate the leading features of JBlend with their
offerings."

    "Consumers demand Java-driven applications on
their mobile phones," said Brandon Tolany, operations
manager of the multimedia applications division for
Freescale Semiconductor.  "Given our market leading
family of i.MX applications processors, 3G platforms and
revolutionary MXC architecture, coupled with the expertise
and portfolio of Aplix and NVIDIA, this collaborative
demonstration provides the solutions manufacturers need to
deliver true multimedia-enabled handsets."

    "The combination of Freescale's i.MX processor and
the NVIDIA GoForce 5500 handheld GPU provides the ultimate
3D performance platform for the Aplix JBlend Java
solution," said Michael Rayfield, general manager of
handheld GPUs at NVIDIA.  "In addition, NVIDIA's close
collaboration with Aplix ensures that content is fully
optimized to take advantage of hardware acceleration for a
compelling and immersive user experience."

    The 3GSM World Congress 2006 will be held from February
13 - 17 in Barcelona, Spain.

    The demonstration will be in Freescale's stand, located
at B37.

    About Aplix Corporation

    Aplix Corporation is the global leader in deploying
Java technology in mobile phones.  Aplix was first
established in 1986 and has been a Sun Java licensee since
1996.  Aplix was publicly listed on the Tokyo Stock
Exchange (Mothers) in 2003.  On August 24, 2004 Aplix and
the Taiwan based company iaSolution finalized the
integration of the corporations. 

    Headquarters: Tokyo

    Regional offices: San Francisco, Munich, Taipei,
Shanghai, Beijing, and Korea (in progress)

    For more information, please visit:
http://www.aplixcorp.com and http://www.iasolution.net .

    About the JBlend Platform

    The JBlend platform is the de facto solution for
running Java applications and services in consumer
electronics devices, including mobile phones.  The platform
has been licensed by over 50 companies as of December 2005.

    JBlend technology:

    -- Sets the pace by maintaining market leadership
through innovation. 

    -- Has proven results, enabling first-to-market
deliveries for our customers. 

    -- Over 150 million mobile phones and consumer
electronics devices have been 
       shipped with JBlend as of September 2005.

    About NVIDIA Corporation 

    NVIDIA Corporation is the worldwide leader in
programmable graphics processor technologies.  The Company
creates innovative, industry-changing products for
computing, consumer electronics, and mobile devices. 
NVIDIA is headquartered in Santa Clara, CA and has offices
throughout Asia, Europe, and the Americas.  For more
information, visit http://www.nvidia.com .
 
     -- JBlend and all related trademarks thereto are
trademarks or registered 
        trademarks of Aplix Corporation in Japan and other
countries.

     -- Java and all other Java-based marks are trademarks
or registered 
        trademarks of Sun Microsystems, Inc. in the United
States and other 
        countries.

     -- All other product or service names are the property
of their 
        respective owners.

    For more information, please contact:

     Akiko Sharp Doi,
     Aplix Corporation
     Tel:   +1-415-558-8800
     Email: pr@aplixcorp.com
     Web:   http://www.aplixcorp.com

SOURCE  Aplix Corporation
2007'02.01.Thu
Convenos Meeting Center and Skype Give Voice to Online Meetings
February 14, 2006

Convenos Meeting Center Is Skype Certified!
    SCOTTS VALLEY, Calif., Feb. 14 /Xinhua-PRNewswire/ --
Convenos, provider of online meeting and collaboration
services, today announced that Convenos Meeting Center, a
Web conferencing and collaboration solution, is Skype(TM)
certified.  Convenos Meeting Center integrates meeting
workspaces and Skype calls, making online collaboration
truly cost effective and convenient.  Convenos Meeting
Center is available for 14-day trial or purchase from the
Convenos Web site at: http://www.convenos.com/trynow.html
.

    "Today's businesses are global in nature and
require solutions that are convenient and cost effective to
boost productivity and process improvements," says
Thomas Torf, CEO of Convenos. "At Convenos, we are
designing products to meet the demand for real-time
collaboration solutions which clearly target process and
productivity improvements, as well as cost reductions.  By
integrating Skype, Convenos Meeting Center enables groups
of employees, customers, partners, and/or suppliers to
collaborate and communicate more effectively at a fraction
of the cost of other web conferencing tools." 

    The Yankee Group has also found that
software-as-a-service is gaining ground in the business
applications market, as more than 60% of SMBs attribute
"lower expense rates" and "increases in
productivity" as driving factors for adopting
software-as-a-service.

    Convenos Meeting Center offers subscription-based,
flat-fee pricing and ease-of-use, combines the cost-saving
advantages of Skype and a full set of industry-standard
features, and is designed to ensure customers unprecedented
value. With Convenos' flat-fee subscription hosts and
attendees can meet as often and as long as they want,
without incurring any additional meeting or telephone
costs. 

    Advantages of Convenos Meeting Center include:

    -- Unlimited online meetings hosted on Convenos
servers

    -- Integrated Internet calling with no additional
per-minute charges 

    -- Industry-standard document, presentation, and
application sharing 

    -- Convenient meeting and attendee management from a
secure, personalized  
       web page 

    -- Value-add tools such as chat, whiteboard, notes, and
on-demand polling

    -- A range of meeting types, from instant meetings to
presence-aware        
       virtual workspaces 

    -- Archival meeting details with persistent storage of
shared meeting        
       content 

    -- Flat-fee pricing and absolutely no additional
per-minute telephone        
       charges

    Pricing and Availability 

    Convenos Meeting Center is currently available for
trial registrants and purchase from the Convenos website,
http://www.convenos.com .  Trial registrants have free and
unlimited usage of a full-featured version of Convenos
Meeting Center, including application sharing, polling,
integrated Internet conferencing, for two weeks.  After the
trial period, Convenos Meeting Center is available for
purchase for $30 per month or $300 per year, per host. 
Each Convenos Meeting Center subscription provides a named
user the ability to host an unrestricted number of
meetings. 

    ABOUT SKYPE

    Skype is the world's fastest-growing service for
Internet communication, allowing people everywhere to make
unlimited voice calls for free.  Skype is available in 27
languages and is used in almost every country around the
world. Skype generates revenue through its premium service
offerings such as making and receiving calls to and from
landline and mobile phones, as well as voicemail and call
forwarding services.  Skype also has relationships with a
growing network of hardware and software providers.  Skype
is an eBay company (Nasdaq: EBAY). To learn more visit
http://skype.com . 

    ABOUT CONVENOS MEETING CENTER

    Convenos Meeting Center is a powerful yet easy-to-use
online collaboration environment which enhances
productivity at any size organization.  Convenos Meeting
Center is simple and convenient to set-up and use,
regardless of whether sessions are scheduled regularly or
ad-hoc.  The flat-fee pricing model is easy to understand
and keeps an organization's collaboration costs predictable
and under budget.  Convenos Meeting Center is certified with
Skype(TM) and integrated with Microsoft(R) Outlook to make
it even easier and more intuitive for users to enjoy the
advantages of online collaboration. 

    ABOUT CONVENOS
    
    Convenos is dedicated to delivering online
collaboration tools that are simple, convenient, and
continue to advance the web-based collaboration and
conferencing industries.  Our products and services target
innovations in the virtual workspace arena which leverage
the convergence of web collaboration and on-demand
applications and respond to business drivers in multiple
industries and within businesses of any size.  Convenos is
committed to simplicity and convenience for the end user,
easy implementation and management for the IT organization,
excellence in the areas of security and compliance, and
demonstrable value-add for all bottom-line stakeholders.
For more information, please visit http://www.convenos.com
. 

    NOTE: Convenos(TM) and the Convenos logo are registered
trademarks of Convenos Corporation.  All product and company
names mentioned herein may be the trademarks of their
respective owners.

    For more information, please contact:

     Rebecca Cavagnari, 
     Tel:   +1-831-713-4609
     Fax:   +1-831-713-4605
     Email: rcavagnari@convenos.com

SOURCE  Convenos Corporation

2007'02.01.Thu
BioWa and Aphton Announce Licensing of BioWa's POTELLIGENT(TM) Technology
February 14, 2006

Aphton to Use BioWa's POTELLIGENT(TM) Antibody Technology for Development of Preclinical IGN312 Anti-Lewis Y antibody
    PRINCETON, N.J. and PHILADELPHIA, Feb. 14
/Xinhua-PRNewswire/ -- BioWa, Inc. and Aphton Corporation
today announced that BioWa has granted a non-exclusive
license to Apthon's wholly-owned subsidiary, Igeneon, to
use BioWa's POTELLIGENT(TM) technology for the development
of IGN312, a humanized monoclonal Lewis Y-specific
antibody. Aphton, through Igeneon, develops IGN312 as a
next-generation antibody based on IGN311, which is
currently in a Phase I/II clinical trial in patients with
Lewis Y-positive cancers. 

    Aphton plans to use BioWa's POTELLIGENT(TM) technology
for the development of a next-generation Lewis Y-specific
antibody with enhanced antibody-dependent cellular
cytotoxicity (ADCC).  Lewis Y is a tumor-related antigen
expressed in up to 90% of all epithelial cancers, which
include breast, colon, gastric and pancreatic cancers.
BioWa's POTELLIGENT(TM) technology has the potential to
increase the ADCC activity of an antibody, resulting in
greater capacity to destroy tumor cells.

    "We are very pleased to be working with an
innovative cancer immunotherapy company like Igeneon, who
has successfully progressed its antibody program to the
clinical stage," said Nobuo Hanai, Ph.D., President
and CEO of BioWa, Inc.  "This licensing agreement
enforces BioWa's strategy to bring about more effective and
safe treatments for cancer." 

    "We look forward to the rapid application of the
POTELLIGENT(TM) technology, which has the potential to
effectively increase the potency of IGN312 as an
anti-cancer treatment," said Patrick Mooney, MD,
Chairman and CEO of Aphton Corporation. "Entering into
this partnership with BioWa is an important step in our
efforts to continue to develop promising product candidates
to fuel our clinical pipeline in the future." 

    This agreement was mediated by FHR Consult (
http://www.fhrconsult.com ) on behalf of BioWa.

    About IGN311 and IGN312 

    IGN311 is a humanized monoclonal antibody against the
Lewis Y carbohydrate antigen, a blood-group-related
oligosaccharide. Lewis Y is over-expressed in up to 90% of
all epithelial cancers and its expression on adult normal
tissues is very restricted; hence IGN311 has the potential
to target a broad range of carcinomas.  IGN311 is designed
to exert clinical effects by destruction of tumor cells by
activation of effector functions and by selective growth
inhibition via functional receptors.  IGN312 is a
next-generation antibody based on IGN311.

    About Aphton Corporation

    Aphton Corporation, headquartered in Philadelphia,
Pennsylvania, is a clinical stage biopharmaceutical company
focused on developing targeted immunotherapies for cancer. 
Aphton's products seek to empower the body's own immune
system to fight disease. Through the acquisition of Igeneon
AG in March 2005, Aphton acquired late-stage products,
IGN101, a cancer vaccine designed to induce an immune
response against EpCAM-positive tumor cells, as well as
IGN311 and IGN312. Aphton has strategic alliances with Xoma
for treating gastrointestinal and other gastrin-sensitive
cancers using anti-gastrin monoclonal and other antibodies;
Daiichi Pure Chemicals for the development, manufacturing
and commercialization of gastrin-related diagnostic kits;
and Celltrion for the development, manufacturing and
commercialization of IGN311 in certain countries in Asia. 
Aphton's most advanced product, Insegia(TM), targets the
hormone, gastrin 17, in an attempt to treat
gastrointestinal cancers. Aphton is currently seeking
partners to support the further development of Insegia. For
more information about Aphton or its programs please visit
Aphton's website at http://www.aphton.com .

    About POTELLIGENT(TM) Technology 

    ADCC activity is an important function of the human
immune system, whereby immune cells can kill target cells,
e.g. cancer cells.  As demonstrated by several anti-cancer
therapeutic antibodies in the market today, ADCC activity
plays a critical mechanism in the killing of tumor cells. 
Enhancement of this activity is one promising approach in
the next generation of antibody technologies. 
POTELLIGENT(TM) technology involves the reduction of the
amount of fucose in the carbohydrate structure of an
antibody.  Research shows that POTELLIGENT(TM) technology
significantly enhances ADCC activity in vitro and in vivo.
One potential benefit of POTELLIGENT(TM) technology derived
therapeutic antibodies is greater tumor cell killing
activity than with conventional antibodies. 

    About BioWa, Inc.

    BioWa, Inc. is a wholly owned subsidiary of Kyowa Hakko
Kogyo Co., Ltd., Japan's leading pharmaceutical and largest
biotech company. BioWa is the exclusive worldwide licensor
of POTELLIGENT(TM) technology, which creates high ADCC
monoclonal antibodies. BioWa is currently developing ADCC
enhanced monoclonal antibody-based therapeutics to fight
cancer, asthma and other life-threatening and debilitating
diseases and both BioWa and Kyowa have POTELLIGENT(TM)
antibody products in various clinical stages.  BioWa
creates and develops enhanced ADCC antibodies for itself
and others, offering a full range of antibody discovery and
development capabilities.  For more information about BioWa
visit its web site at http://www.biowa.com .

    POTELLIGENT(TM) is the trademark of Kyowa Hakko Kogyo
Co., Ltd.  All rights are reserved.

    Safe Harbor

    This press release includes forward-looking statements
within the meaning of the federal securities laws,
including statements about Aphton's expectations regarding:
(1) Aphton's plan to use BioWa's POTELLIGENT(TM) technology
for the development of a next-generation Lewis Y-specific
antibody with enhanced antibody-dependent cellular
cytotoxicity; (2) the potential of BioWa's POTELLIGENT(TM)
technology to increase the ADCC activity of an antibody,
resulting in greater capacity to destroy tumor cells; (3)
the potential benefits to Aphton resulting from the
licensing agreement, including the rapid application of the
POTELLIGENT(TM) technology in an attempt to effectively
increase the potency of IGN312 as an anti-cancer treatment;
(4) Aphton's belief that this new relationship with BioWa is
an important first step in Aphton's efforts to continue to
develop promising product candidates to fuel Aphton's
clinical pipeline in the future; (5) the potential of
IGN311 to target a broad range of carcinomas, destroy tumor
cells, and exert clinical effects by destruction of tumor
cells; and (6) Aphton's intent to seek partners to further
support the development of Insegia. These forward-looking
statements may be affected by risks and uncertainties that
could cause the actual results to differ materially from
those expressed in such forward-looking statements. Aphton
undertakes no obligation to update forward-looking
statements to reflect events or circumstances after the
date hereof. This information is qualified in its entirety
by cautionary statements and risk factor disclosure
contained in Aphton's Securities and Exchange Commission
filings, including Aphton's report on Form 10-K filed with
the Commission on March 16, 2005. These risk factors
include, but are not limited to: (1) the risks and
uncertainties inherent in the drug development process and
in Aphton's business; (2) the ability of Aphton and BioWa
to successfully collaborate in the research and development
of IGN312; (3) the possibility that BioWa's POTELLIGENT(TM)
technology may not have the desired effect on antibodies;
(4) the timing or results of ongoing and future clinical
trials for IGN312; (5) the ability of Aphton to obtain
regulatory approval for IGN312, fund the development,
manufacture and commercialization of IGN312, and gain
commercial acceptance of IGN312; (6) the ability of any
approved third parties to manufacture and supply IGN312 in
commercial quantities; (7) the ability of Aphton to fund
the development, manufacturing and commercialization of
IGN312; (8) Aphton's ability to find a partner who will
support the further development of Insegia; (9)
intellectual property risks; (10) the impact of competitive
products and pricing; and (10) changing economic
conditions.

    For more information, please contact:  

     Nobuo Hanai, Ph.D., 
     President and CEO
     BioWa, Inc.
     Tel:   +1-609-580-7500 x7501

     Martina Molsbergen, 
     Vice President, Business Development
     BioWa, Inc.
     Tel:   +1-609-580-7500 x7506

     Patrick Mooney, 
     M.D., President and CEO, 
     Aphton Corporation
     Tel:   +1-215-218-4377

     Gerda Redl, Ph.D., 
     Vice President, Business Management
     Aphton Corporation
     Tel:   +43-1-90250-122

SOURCE  BioWa, Inc.
2007'02.01.Thu
Human Heart Anatomy 3D Models, Pictures and Animation Available at 3DScience.com
February 14, 2006

Zygote Media Group Releases Zygote Human Heart 3, the Most Sophisticated 3D Heart Model Ever
    SALT LAKE CITY, Feb. 14 /Xinhua-PRNewswire/ -- Zygote
Media Group, Inc., the leading provider of world-class 3D
biomedical models, images and animations, today announced
the public availability of the Zygote Human Heart 3, the
most sophisticated 3D heart model ever.  The Zygote heart
is the only known animated 3D heart model available for
licensing in the world.

    (Photo: 
http://www.newscom.com/cgi-bin/prnh/20060213/LAM154-a 
            
http://www.newscom.com/cgi-bin/prnh/20060213/LAM154-b )

    New detail from MRI and CT data make the imagery as
close to the real thing as anything existing on the market
today.  Zygote Human Heart 3 makes it easy for graphics
designers, scientists and animators to visualize the human
heart, from exteriors and cut views of the interior to an
accurate animation of the cardiac cycle.  The model and
images are available for immediate licensing at
http://www.3DScience.com .

    "Zygote Human Heart 3 is a breakthrough product. 
Not only is it the greatest heart 3D model ever, it is one
of those once-in-a-generation products that redefines its
category," said Bryan Brandenburg, CEO of Zygote Media
Group.  "This is the first and only animated 3D heart
model ever to be derived from high resolution MRI and CT
data and available for licensing.  If a picture is worth a
thousand words, then this animation is worth
millions."

    The Zygote Human Heart 3 offers customers:

    -- More MRI/CT human heart detail with a reduced
polygon count

    -- Full human heart cardiac cycle that includes cutaway
interior views

    -- Two high resolution photorealistic exterior texture
maps for both a lean 
       and fatty heart derived from human heart digital
photos

    -- Support for most major 3D applications including
Maya, 3D Max, 
       Lightwave, Cinema4D, Softimage, Shade and Generic
OBJ

    The Highest Detailed 3D Heart Model Ever

    Almost any view of the human heart can be visualized,
including human heart diagrams, heart anatomy pictures, and
accurate human heart animations.  The virtual heart model
features cuts so not only is the interior viewable at great
detail, but is also revealed while animating the cardiac
cycle.

    Pricing and Availability

    The Zygote Human Heart 3 retail price starts at $1,200.
 From now until March 15, there is an introductory discount
of 30%.  Students, educators and educational institutes
receive an additional 30% off as part of 3DScience.com's
educational discount program.  Texture maps, cuts and
animation files can be purchased separately.  Other heart
models are also available including the standard heart for
$99 and a solid heart model for design and engineering at
$2,500. 

    About Zygote Media Group 

    With more than 11 years of development, Zygote's
library of licensable content boasts the most comprehensive
and accurate collections of anatomical 3D models available
in the world.  Zygote is located near Salt Lake City, Utah
and can be found at http://www.zygote.com , or by calling
(801) 765-4141. 

    About 3DScience.com 

    3DScience.com is an online marketplace and community
dedicated to scientific visualization and supporting
educators around the world.  3DScience.com is the home of
the Zygote Male and Female Anatomy 3D Model collections. 
http://www.3DScience.com also provides a wide range of 3D
Models, stock medical illustrations as well as the highest
quality library of free medical clip art available on the
World Wide Web.  3DScience.com is powered by GoECart.com
Shopping Cart Software.

    Note:
    Content for the media can be found at:

    Human Heart Pictures available as Free Clip and
Licensing at higher 
    resolution
   
http://www.3dscience.com/human_heart_anatomy_pictures.asp

    Human Heart Anatomy Diagrams
   
http://www.3dscience.com/human_heart_anatomy_diagram.asp

    Human Heart Anatomy Animation
    http://3dscience.com/heart_model_animation.asp 

    Human Heart Model
    http://3dscience.com/human_anatomy_3d_heart_model2.asp


    Valentine's Day Heart, Valentine's Heart
    http://3dscience.com/valentines_day_heart.asp 

    For more information, please contact:

     Tim Rush,
     Snapp Norris Group,
     Zygote Media Group, Inc. 
     Tel:    +1-801-208-1100
     Email:  tim.rush@sng.com,

SOURCE  Zygote Media Group, Inc.
2007'02.01.Thu
Sughrue Mion to Host Mock Trial Seminar in Korea
February 14, 2006

February 27-28 Event Will Detail Workings of U.S. Jury System;
International Trade Commission
    WASHINGTON, Feb. 14 /Xinhua-PRNewswire/ -- Sughrue Mion
PLLC, a leading global intellectual property law firm,
announced today that they will sponsor a two-day mock trial
seminar at Kangnam GS Tower in Seoul in conjunction with the
Korean Patent Attorneys Association (KPAA).  The program
will highlight the difficult and unique challenges that
Korean companies face when confronted with patent
litigation in U.S. federal courts and before the
International Trade Commission (ITC). 

    "As a firm that has been active in the U.S. and
Asia for decades, we've seen a trend as Asian companies
become more aggressive in enforcing their own
patents," Bill Mandir, a Sughrue Mion partner who led
the design of this program, said.  "These battles
often get played out with U.S. patents in U.S. district
courts and the ITC because of the enormous market the U.S.
offers. After the success of our Japanese mock trial
events, we recognized the importance of reaching an even
greater breadth of our Asian clients."

    The mock trial will be presented to an American-style
jury and presided over by the Honorable James F. Stiven, a
retired U.S. Magistrate for the Southern District of
California with more than 35 years of trial experience. The
250 Korean in-house counsel and corporate managers expected
to attend the event will be able to see exactly how a jury
deliberates and the issues that are of paramount concern to
them. 

    The trial itself will center on a mock case where a
U.S. plaintiff has alleged that a Korean defendant has
infringed on patented technology for golf club grips.  The
courtroom will be modeled after a U.S. courtroom, and all
aspects of the litigation and deliberation will be filmed
so that participants can see what happens during the trial
and in the jury room.

    "The ITC continues to be an increasingly popular
venue for patent litigation, so it was important to add
this element to the mock trials in Korea," John
Rabena, a Sughrue Mion partner, said.  "Through this
mock trial we will help explain the differences between
U.S. and Korean courts -- and the differences between
district courts and the ITC -- and help our clients develop
a winning strategy if they are called into a case.  And, as
a result of this experience, we expect companies will see
how to better build their patent portfolios to avoid
litigation altogether."

    Sughrue partners Steve Gruskin, Carl Pellegrini, and
John Scherling, all of whom have extensive litigation
experience, have also been involved in planning the mock
trial.

    To register for the event, please download the
registration form at http://www.kpaa.or.kr , call the
Korean Patent Attorneys Association at 
822-8486-8486, or email gn@kpaa.or.kr.  

    About Sughrue Mion, PLLC

    Sughrue Mion, PLLC, is one of the largest law firms
practicing exclusively in the field of intellectual
property law. Based in Washington, D.C. with offices in
Silicon Valley, San Diego, and Tokyo, Sughrue specializes
in litigating intellectual property matters in federal
district court and before the International Trade
Commission.  Sughrue has obtained more patents than any
other firm in the country.  For more information please
visit http://www.sughrue.com .

    For more information, please contact:

     Melissa Maslar,
     Sughrue Mion PLLC
     Tel:    +1-202-973-1336
     Mobile: +1-202-276-0070
     Email:  mmaslar@levick.com, 

SOURCE  Sughrue Mion PLLC
2007'02.01.Thu
Merrill Corporation Files Registration Statement for Initial Public Offering
February 14, 2006

    ST. PAUL, Minn., Feb. 14 /Xinhua-PRNewswire/ -- Merrill
Corporation today announced that it has filed a registration
statement with the U.S. Securities and Exchange Commission
in connection with a proposed initial public offering of
its common stock.  The proposed offering will include
shares sold by Merrill Corporation and by certain of
Merrill's stockholders including DLJ Merchant Banking
Partners II, L.P.  Deutsche Bank Securities Inc. and Credit
Suisse Securities (USA) LLC will be acting as joint
book-running managers and Piper Jaffray & Co. will be a
co-manager.

    The number of shares to be offered and the price range
for the offering have not yet been determined.  The
offering will be made only by means of a prospectus.  When
available, copies of the preliminary prospectus relating to
this offering may be obtained from Deutsche Bank Securities
Inc., Prospectus Department, Floor 25, 1251 Avenue of the
Americas, New York, NY 10020, (212) 250-2500 or Credit
Suisse Securities (USA) LLC, Prospectus Department, Eleven
Madison Avenue, Level 1B, New York, NY 10010, (212)
325-2580.

    A registration statement relating to these securities
has been filed with the Securities and Exchange Commission,
but has not yet become effective.  These securities may not
be sold nor may offers to buy be accepted prior to the time
the registration statement becomes effective.  This press
release shall not constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any
sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities
laws of any such state or jurisdiction.

    About Merrill Corporation

    Merrill Corporation, headquartered in St. Paul,
Minnesota, is a leading provider of outsourcing solutions
for various complex business communication and information
management needs.  Merrill's services include document and
data management, litigation support, branded communication
programs, fulfillment, imaging and printing. 

    Forward-Looking Statements

    Certain statements in this press release constitute
"forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. 
Such forward-looking statements are subject to various
risks, uncertainties and assumptions that could cause
actual results to differ materially from those contained in
the forward-looking statements.  A discussion of the factors
that could cause results to differ materially is included in
Merrill Corporation's Form S-1 filed with the Securities and
Exchange Commission.

    For more information, please contact:

     Craig Levinsohn,
     Merrill Corporation
     Tel:    +1-651-632-4505
     Email:  Craig.levinsohn@merrillcorp.com

SOURCE  Merrill Corporation 
2007'02.01.Thu
Aviation Week Named Official Media Partner for Singapore Air Show
February 14, 2006

New Ownership of Singapore's Changi International Air Show Invests in New Airport Location, Facilities and Partnerships to Accommodate Region's Booming Aviation, Aerospace and Defense Market
    NEW YORK, Feb. 14 /Xinhua-PRNewswire/ -- McGraw-Hill
Aerospace & Defense has reached agreement with the new
ownership of the Singapore Air Show, to be its Official
Media Partner commencing with the February 26-2 March, 2008
event at Singapore's Changi International Airport.

    McGraw-Hill A&D and its Aviation Week information
and media products will support the Singapore show, now
known as Changi International Airshow (CAS)  with print,
electronic and event access to its audience of 1.2-million
aviation, aerospace and defense professionals in 180
countries.  

    The agreement includes cooperative advertising, event
advisory, exclusive distribution points, and marketing
programs.  Aviation Week & Space Technology and
Aviation Week ShowNews, a daily magazine produced on-site
in Singapore, will be the lead publications for CIAS.  In
addition, the group's Business & Commercial Aviation,
Overhaul & Maintenance, Defense Technology
International, AviationNow.com, and Aviation Week
Conferences & Exhibitions will be involved in the
global communications program for the air show.

    "Our relationships with the Singapore business
community, the show organizers and the Asian aerospace
industry spans several decades, and we welcome this
opportunity to step up to a new level of involvement and
support as the region paces development in aerospace and
defense," said McGraw-Hill Aerospace & Defense
Executive Vice President/Publisher Kenneth E. Gazzola
"Moreover, our media and information services lend a
powerful foundation as the event transitions to new
ownership and venue."

    The new ownership of CAS is investing millions to
elevate the importance of the event.  This includes moving
the event to a new runway with access to the static line,
new exhibit chalet and exhibition facilities, installing a
modern communications and IT infrastructure, and reaching
an agreement with a new media partner that can bring a
global, multimedia presence to the show. 

    "Aviation Week provides the Changi International
Airshow with global leadership in all key world regions and
industry sectors, including commercial air transport,
military, space, business aviation and MRO," said
Jimmy Lau, Managing Director, of CAS.  "In addition,
our growing event and markets provide Aviation Week a new
level of visibility throughout Asia."

    About McGraw-Hill Aerospace & Defense 

    McGraw-Hill Aerospace & Defense, a division of The
McGraw-Hill Companies, is the largest multimedia
information and services provider to the global aviation
and aerospace industry, and includes publications such as
Aviation Week & Space Technology, Defense Technology
International, Aviation Daily, Overhaul & Maintenance,
Aerospace Daily & Defense Report, ShowNews, Business
& Commercial Aviation, The Weekly of Business Aviation,
and the World Aerospace Database and its print companion,
World Aviation Directory.  The group's web portal,
http://www.aviationnow.com , offers the industry's most
reliable news, information, intelligence and features, and
its Aviation Week Intelligence Network (AWIN) at
http://www.aviationweek.com/awin is the industry's most
integrated business tool for managers, business developers,
buyers and technical professionals across the entire
aviation and aerospace field. McGraw-Hill A&D also
produces 12 executive events in the MRO and Programs and
Defense sectors.

    About The McGraw-Hill Companies

    Founded in 1888, The McGraw-Hill Companies is a leading
global information services provider meeting worldwide needs
in the financial services, education and business
information markets through leading brands such as Standard
& Poor's, McGraw-Hill Education, BusinessWeek and J.D.
Power and Associates.  The Corporation has more than 290
offices in 38 countries. Sales in 2005 were $6.0 billion.
Additional information is available at
http://www.mcgraw-hill.com .

    About Changi International Airshow

    Changi International Airshow (CAS) will be held in
Singapore on a biennial basis, beginning 26 February 2008.

    The event is organized by Changi International Airshow
& Events Pte Ltd., a joint venture between the Civil
Aviation Authority of Singapore (CAAS) and the Defence
Science & Technology Agency (DSTA), a subsidiary of
Singapore's Ministry of Defence.

    Managing Changi International Airshow & Events Pte
Ltd are Chairman, Lim Chin Beng, an aviation veteran, and
Jimmy Lau, former Managing Director of Asian Aerospace Pte
Ltd.

    For more information, please contact:

     Rob Kulat
     Kulat Communications
     Tel:   732-219-5816
     Email: kucomm@hotmail.com 

SOURCE  McGraw-Hill Aerospace & Defense
2007'02.01.Thu
TCOM Announces Quarterly Operating Statistics for the Period Ended December 31, 2005
February 14, 2006

    HONG KONG, Feb. 14 /Xinhua-PRNewswire/ -- Telecom
Communications, Inc. (OTC Bulletin Board: TCOM) the Total
Solutions Provider, announced operating statistics for the
quarter ended December 31, 2005.

    Revenues increased $2,752,761 or 174.7% due primarily
to:  Revenues recorded at $4,328,099 for the three months
period ended December 31, 2005 compared to $1,575,338 for
the same period ended December 31, 2004.  The increase of
$2,752,761 due primarily to the initial receipt of rights
to first use the software of $2,400,000.  Revenues for the
period ended December 31, 2005 were generated from the
fixed monthly income by providing clients our products
namely Total Solutions, SEO4Mobile and IBS V4.1.

    Net income was up 35.9% to $493,368 for the three month
period ended December 31, 2005 compared to $362,965 for same
period ended December 31 of 2004.

    "Our first quarter 2006 results include strong
performance in total solutions product lines and IBS v4.1
SMEs sales," said Tim Chen, president and CEO of TCOM.
 "We are encouraged by the fact that IBS v4.1 sales
continue to build momentum and generate increased interest
from SMEs Internet businesses business.  Cash used during
the quarter includes our continued investment in our SME
software system developments called IBS v5.0 as BtoBtoC
e-commerce value chain, and entertainment content service
offerings."

    TCOM will report its 1st quarter 2006 financial results
within this week.

    About Telecom Communications, Inc. 

    Telecom Communications, Inc. is a Total Solutions
Provider that offers Integrated Communications Network
Solutions and Internet Content Services in universal voice,
video, data web and mobile communications for interactive
media applications, technology and content leaders in
interactive multimedia communications.  It develops,
markets and sells a universal media software solution for
enterprise-wide deployment of integrated voice, video, data
web and mobile communications and media applications. 
Telecom Communications, Inc. does business in Asia via its
wholly owned subsidiaries, Alpha Century Holdings Ltd and
3G Dynasty Inc. (http://www.icstarmms.com ; 
http://www.skyestar.com ).  icstarmms.com currently
provides entertainment contents to 64 China Internet
companies including: http://www.Baidu.com , Shanghai
Linktone, 3721.com -- a Yahoo company,  Kongzhong Corp.,
http://www.QQ.com and http://www.eLong.com under the
cooperation partnership agreements.  

    About IBS v4.1 Enterprise Suite 

    The product line focuses on the one million SMEs in
China, with version 4.1 enterprise suite being satiable to
all companies with less than 500 employees, inner
information resource management and affiliate networks,
vendor/customer, information process and communications
over the Internet and wireless communications.  This
product has strong customer relations and interactive
management, straight to the end consumer via MoDirect. 
Most SMEs have only small budgets for promotion, marketing
and customer management.  They can use IBS v4.1 at the
lowest cost to publish ads on the web and SEO4Mobile mobile
phone users.  The product allows quick and easy interaction
between company and customer straight to the end consumers.


    Safe Harbor 

    The statements made in this release constitute
"forward-looking" statements, usually containing
the words "believe," "estimate,"
"project," "expect," or similar
expressions.  These statements are made pursuant to the
safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.  Forward-looking statements inherently
involve risks and uncertainties that could cause actual
results to differ materially from the forward-looking
statements.  Factors that would cause or contribute to such
differences include, but are not limited to, changing
economic conditions, interest rates trends, continued
acceptance of the Company's products in the marketplace,
competitive factors and other risks detailed in the
Company's periodic report Filings with the Securities and
Exchange Commission.  By making these forward-looking
statements, the Company undertakes no obligation to update
these statements for revisions or changes after the date of
this release. 

     For more information, please contact:

      Ms. Sandy Tang
      Telecom Communications, Inc.
      Tel:   +852-2782-0983
      Email: pr@tcom8266.com

SOURCE  Telecom Communications, Inc.

2007'02.01.Thu
February 14, 2006
    DUSSELDORF, Germany, Feb. 14 /PRNewswire/ -- After the
successful completion of clinical studies, the German
biotech company Orthogen AG (Dusseldorf) intends to build
up a Europe-wide distribution of Orthokine(R). 
Orthokine(R) is a medical device for the production of
autologous conditioned serum; containing anti-inflammatory
cytokine antagonists and growth factors.  Two universities
performed randomized double-blind studies demonstrating its
high efficacy and safety in the therapy of osteoarthritis of
the knee and low back pain.  "Due to its beneficial
side effect profile, Orthokine(R) therapy represents an
efficient alternative to steroids, hyaluronic acids and
analgesics like cox-II inhibitors," said Prof. Dr.
Peter Wehling, CEO of Orthogen, today. 

    After the build up of the Germany-wide sales in the
last year, the molecular orthopedics specialist company
intends to extend its activities to the EU market.  FDA
application for the sales in the US market is filed. 

    Orthogen AG works currently on a novel stem cell
technology for the regeneration of cartilage from
non-embryonic stem cells.  First clinical results on humans
demonstrate feasibility of the method.  It is intended to
replace time-consuming autologous chondrocyte implantation
(ACI) by this new procedure. 

    A new immune-modulatory therapeutic approach for the
treatment of rheumatoid arthritis with so-called exosomes
is also under development. Exosomes are highly efficient
anti-inflammatory nano-particles.  Clinical studies
demonstrated feasibility and safety of the method.  Further
clinical studies are intended to show long-term-efficacy. 
This method could become a highly efficient and safe
alternative to cytokine antagonists produced with
recombinant techniques (e.g. Anti-TNF). 

    Orthogen AG is a biopharmaceutical group of companies
which has worked for twelve years in the field of molecular
orthopedics. 

    For more information, please contact:

     Antje Kassel
     Public Relations
     Orthogen AG
     Tel:     +49-(0)211-387-0076
     Mobile:  +49-173-240-2901
     Fax:     +49-(0)211-387-0010
     Email:   akassel@orthogen.com
     Website: http://www.orthogen.com

SOURCE  Orthogen AG
2007'02.01.Thu
February 13, 2006
ANADIGICS' New HELP3(TM) HSDPA-Compliant WCDMA Power Amplifiers Offer Industry-Leading Efficiency and Integration to Extend Talk-Time
    BARCELONA, Spain, Feb. 13 /Xinhua-PRNewswire/ -- 3GSM
World Congress 2006 -- ANADIGICS, Inc. (Nasdaq: ANAD), a
leading supplier of wireless and broadband solutions, today
introduced its third generation High-Efficiency-at-Low-Power
(HELP3(TM)) wideband CDMA (WCDMA) power amplifiers (PAs).
The Company's HELP3(TM) WCDMA PAs offer the industry's
lowest power consumption and provide full compliance with
High Downlink Packet Access (HSDPA) requirements, enabling
ultra-fast multimedia access, while extending battery life.
 The complete family of HELP3(TM) WCDMA PAs has been
optimized for power and space sensitive 3G devices,
including handsets, smart phones, data cards, and embedded
notebook applications.

    "ANADIGICS is raising the performance bar for 3G
power amplifiers with our latest generation of HELP(TM)
products," said Dr. Ali Khatibzadeh, Senior Vice
President and General Manager of Wireless Products at
ANADIGICS.  "Our HELP3(TM) HSDPA-compliant power
amplifiers offer the industry's best current consumption,
allowing mobile users to experience the full potential of
3G services."

    ANADIGICS' HELP3(TM) PAs use the Company's exclusive
InGaP-Plus(TM) technology, which integrates bipolar and
field-effect transistor (FET) devices on the same InGaP
GaAs die.  Through selectable bias modes, the HELP3(TM) PAs
achieve optimal efficiency across the low-range and
mid-range output power levels. The PAs reduce average
current consumption by 75%, compared with a conventional
power amplifier.  This represents an additional 50% average
current consumption savings compared with the first
generation HELP(TM) WCDMA PAs. HELP3(TM) PAs provide
exceptionally low quiescent currents of 7 mA without an
external DC-DC converter. They also incorporate a built-in
reference voltage generator eliminating the need for
external regulators.

    Part Number      Frequency Band          Efficiency    
    Quiescent 
                                                           
     Current

    AWT6273        824 MHz to 849 MHz       45% @ +29 dBm  
       7 mA 
                     (US Cellular)          20% @ +16 dBm 

    AWT6278       1850 MHz to 1910 MHz      43% @ +29.5 dBm
       7 mA
                       (US PCS)             21% @ +16 dBm  
                   

    AWT6279       1920 MHz to 1980 MHz      43% @ +28.5 dBm
       7 mA 
                        (IMT)               21% @ +16 dBm  
                  

    The new power amplifiers are offered in compact 4 mm by
4 mm by 1 mm modules. The products are manufactured using a
materials set consistent with the European Union's
Restriction of Hazardous Substances (RoHS). 

    The AWT6273, AWT6278, AWT6279 are priced at $2.58 in
quantities of 10,000 units. Samples are available now. For
additional information, contact ANADIGICS by phone (908)
668-5000 or FAX (908) 668-5132 or visit the Company's Web
site at http://www.anadigics.com .

    ANADIGICS, Inc. (Nasdaq: ANAD) designs and manufactures
radio frequency integrated circuit (RFIC) solutions for
growing broadband and wireless communications markets. The
Company's innovative high frequency RFICs enable
manufacturers of communications equipment to enhance
overall system performance, and reduce manufacturing cost
and time to market.  By utilizing state-of-the-art
manufacturing processes for its RFICs, ANADIGICS achieves
the high-volume and cost-effective products required by
leading companies in its targeted high-growth
communications markets.  ANADIGICS was the first GaAs IC
manufacturer to receive ISO 9001 certification and is
certified to the ISO 9001:2000 and ISO 14001:2004
international standards.

    Except for historical information contained herein,
this press release contains projections and other
forward-looking statements (as that term is defined in the
Securities Exchange Act of 1934, as amended).  These
projections and forward-looking statements reflect the
Company's current views with respect to future events and
financial performance and can generally be identified as
such because the context of the statement will include
words such as "believe", "anticipate",
"expect", or words of similar import.  Similarly,
statements that describe our future plans, objectives,
estimates or goals are forward-looking statements.  No
assurances can be given, however, that these events will
occur or that these projections will be achieved and actual
results and developments could differ materially from those
projected as a result of certain factors.  Important
factors that could cause actual results and developments to
be materially different from those expressed or implied by
such projections and forward-looking statements include
those factors detailed from time to time in our reports
filed with the Securities and Exchange Commission,
including the Company's annual report on Form 10-K for the
year ended December 31, 2004, and those discussed elsewhere
herein.

    For more information, please contact: 

    Press
     Chuck Manners
     Godfrey
     Tel:   +1-717-393-3831
     Fax:   +1-717-393-1403
     Email: chuck@godfrey.com

    Corporate Contact
     Brian Ribeiro 
     ANADIGICS, Inc.
     Tel:   +1-908-668-5000
     Fax:   +1-908-412-5978
     Email: bribeiro@anadigics.com

    Investor Relations
     Thomas Shields
     ANADIGICS, Inc.
     Tel:   +1-908-412-5995
     Email: tshields@anadigics.com 

SOURCE  ANADIGICS, Inc. 
2007'02.01.Thu
February 13, 2006
    BARCELONA, Spain, Feb. 13 /Xinhua-PRNewswire/ -- 3GSM
World Congress -- From today BullGuard Mobile Anti-virus
will be available as a multi-platform retail pack, for
mobile devices using Windows Mobile and Symbian operating
systems. The pack includes full automatic anti-virus
protection and access to BullGuard Support 24-hours a day.

    BullGuard Mobile Anti-virus retail pack:

     -- 1 Year BullGuard Mobile Anti-virus subscription

     -- Software for Windows Mobile and Symbian Series
60/80/UIQ devices

     -- Available in 16 languages

     -- Includes BullGuard Support

    BullGuard's COO Heini Zachariassen commented on the
product launch:

    "Over the past year we have learned from our
partners that there is great demand for a single retail
product covering all the major mobile platforms.  With this
new retail product covering 5 different operating systems
and allowing users to change device during the subscription
period, we have brought the most complete solution to the
marketplace."

    BullGuard Mobile Anti-virus

    BullGuard Mobile Anti-virus includes constant traffic
monitoring and on-demand scanning in addition to automatic
over-the-air updates. Launched in March 2005, and available
as a retail product for Windows Mobile platforms since June
2005, BullGuard Mobile Anti-virus is a standard
installation on devices sold by leading European operators
including Sonofon, Telefonica, ONE and devices configured
by Dangaard Telecom, Europe's largest mobile phone
distributor.

    Features

     -- On-writing Anti-virus Scanner 
        Scans all files downloaded from the internet or
received via e-mail,  
        SMS, MMS, Bluetooth, IR.

     -- On-demand Anti-virus Scanner 
        Customisable search of selected files/folders.

     -- Over-the-air Virus Definition Updates
        Updates are received and installed automatically.

     -- On-device alerting function
        BullGuard Mobile Anti-virus alerts the user when
malware is identified
        and automatically responds to the threat.

     -- Scan logs
        All recent scans are logged with details of any
malware identified.

     -- Available in 16 languages:
        Arabic, Chinese (Mandarin), Danish, Dutch, English,
Flemish, French,
        German, Greek, Hungarian, Italian, Norwegian,
Portuguese, Russian,
        Spanish and Swedish.

     -- BullGuard Support
        It is central to the BullGuard concept of Security
that our customers
        receive all the assistance needed to fully
appreciate and utilise the
        BullGuard products. BullGuard Support is a free
service, available 24
        hours a day, 365 days a year, offering advice and
assistance whenever it
        is needed.

    About BullGuard

    BullGuard specialises in PC & mobile security
solutions for home-users and small-businesses, emphasising
technical excellence, ease-of-use and customer-care.

    BullGuard is committed to providing simple,
cost-effective, integrated security solutions that provide
users with first-class protection from computer viruses and
intruders.

    BullGuard 6.0 is available as Retail, OEM and ESD.

    BullGuard is headquartered in Copenhagen, Denmark and
has offices in Romania and the United Kingdom.

    For more information, please contact:

     Alexander Staun-Rechnitzer, 
     Information and PR Manager,
     BullGuard
     Mobile: +45-2682-1982
     Email:  alex@bullguard.com 
     Web:    http://www.bullguard.com

SOURCE  BullGuard Ltd.
2007'02.01.Thu
February 13, 2006
Entry Rate Accelerating
    BEIJING, Feb. 13 /Xinhua-PRNewswire/ -- Xinhua China
(OTC Bulletin Board: XHUA) the majority shareholder of the
leading book distributor in China, reported today that it
expects the number of titles entered into its Chapter One
China(TM) system to exceed 10,000 before the end of
February.  The company also expects the number of titles
available through the Chapter One system to continue
increasing beyond that level in the near future.  It said
the rate of entry is accelerating and a wider variety of
titles is being included.

    The only system of its kind in China, Chapter One China
allows book retailers and others in the Chinese market to
preview, through an on-line portal, titles they are
considering stocking in their stores.  Among the titles
being entered are textbooks, engineering and technical
volumes, literature, biographies, historical texts and
other non-fiction.  Titles in Chinese and other languages,
most notably English, are increasingly available for
preview through the system.  Book buyers have the ability
to search the database by title, author, publisher and ISBN
code and review the first chapter of any title before making
a buying decision, according to Xinhua China.

    Xianping Wang, president and CEO said, "The
ability to preview volumes on-line before making purchases
is particularly important in China because of the distances
involved in some areas.  Chapter One China will allow
bookstores in even the farthest provinces to make buying
decisions and stock titles that meet the needs of their
specific customers with the same speed and efficiency
available in major population centers.  

    "Our ultimate goal is to make available for
preview on the Chapter One China system every title
available in the Chinese market.  We have the capacity to
do so and we are well on our way toward that goal,"
Wang added.

    Wang noted that Xinhua China expects the development of
the Chapter One system to be a significant factor in the
growth of its operating subsidiary, Xinhua Publications
Circulation & Distribution Co., Ltd.  "We expect
to benefit from Chapter One in a variety of ways.  We
expect to reach agreements with many of the over 12,800
government-owned Xinhua bookstores, the thousands of
independent bookstores and on-line booksellers under which
we will provide access to the Chapter One system in return
for certain order volume placed through Xinuha C & D. 
We will also provide them with the option to subscribe to
the system for a modest annual fee."

    "The Chapter One system should also prove valuable
to on-line booksellers.  It will allow their customers to
review excerpts before making a purchase -- the equivalent
of browsing through a bookstore.  The growth of on-line
purchasing of books and other publications in China
provides an additional opportunity to grow our business. 
On-line sales require fulfillment services.  We are
uniquely positioned to provide those services by shipping
titles directly to consumers on a fee-for-service basis. 
The number of Internet users in China is projected to reach
600 million by the year 2010.  Internet commerce potentially
represents a major source of revenue and earnings for Xinhua
China," Wang concluded.

    About Xinhua China

    Xinhua China Ltd. is a U.S. publicly traded holding
company that, through one of its subsidiaries, Xinhua
Publications Circulation & Distribution Co., Ltd.,
holds a national license for distribution of books and
other publications in China.  Xinhua China is involved in
forming strategy, operating and financing for Xinhua C
& D.  Xinhua China also interfaces with the worldwide
financial communities to inform them of the combined
companies' goals and developments.  For more information,
please call Mr. Alex Helmel at 1-800-884-3864 ext. 17 or
visit its website at http://www.xinhuachina.com.cn .

    Safe Harbor Statement

    This news release may include forward-looking
statements within the meaning of section 27a of the UNITED
STATES SECURITIES ACT of 1933, as amended, and section 21e
of the UNITED STATES SECURITIES and EXCHANGE ACT of 1934,
as amended, with respect to achieving corporate objectives,
developing additional project interests, Xinhua China's
analysis of opportunities in the acquisition and
development of various project interests and certain other
matters.  These statements are made under the "safe
harbor" provisions of the United States private
securities litigation reform act of 1995 and involve risks
and uncertainties, which could cause actual results to
differ materially from those in the forward-looking
statements contained herein.

    For further information, please contact:

    At Xinhua China Ltd.:             
     Alex Helmel                       
     Investor Relations                
     Tel:   +1-604-681-3864 or +1-800-884-3864      
     Email: info@xinhuachina.com.cn           


    At The Investor Relations Company:
     Woody Wallace or Michael Arneth
     Tel:   +1-847-296-4200
     Email: wwallace@tirc.com or marneth@tirc.com

SOURCE  Xinhua China Ltd.

2007'02.01.Thu
February 13, 2006
22% Consolidated Revenue Growth For The Quarter;
Hospital and Equipment Divisions Report Profitable Operations;
Closedown of Distribution Division in Process
    BETHESDA, Md., Feb. 13 /Xinhua-PRNewswire/ -- Chindex
International, Inc. (Nasdaq: CHDX), an independent American
provider of Western healthcare products and medical services
in the People's Republic of China, today announced results
for the quarter ended December 31, 2005.  The Company will
report a 22% increase in consolidated revenue over the same
quarter of the prior fiscal year and an after-tax loss.  The
Medical Capital Equipment and Healthcare Services divisions
both reported profitable operations while the Healthcare
Products Distribution division accounted for the loss in
the quarter as closedown of operations in this division
were initiated.  

    Revenue for the quarter ended December 31, 2005 was
$27.2 million with a loss from operations of $516,000 and a
net loss of $463,000 or a loss per share of $0.07.  This
compares to revenue of $22.3 million with a loss from
operations of $3.3 million and a net loss of $3.7 million,
or a loss per share of $0.69, for the quarter ended
December 31, 2004. 

    Revenue for the nine months ended December 31, 2005 was
$77.8 million with a loss from operations of $2.8 million
and a net loss of $2.5 million, or a loss per share of
$0.39.  This compares to revenue of $76.6 million with a
loss from operations of $2.8 million and a net loss of $3.6
million, or a loss per share of $0.68, for the nine months
ended December 31, 2004. 

    Roberta Lipson, President and CEO of Chindex commented
from the Company's offices in Beijing: "During the
recent quarter we reported strong revenue growth in the
Healthcare Services segment of 91%, as compared to the
prior year period.  We reported modest revenue growth in
the Medical Capital Equipment segment of 7% in spite of
continuing market challenges.  The results for the period
were a significant improvement over the prior year with
both the equipment and hospital divisions reporting
profitable operations.  In addition, we had a significant
decrease in expenses at the parent company level.  Although
we reported a consolidated loss, it was attributable to the
results of the Healthcare Products Distribution division
which we began closing down following our announcement on
November 23, 2005. 

    "In the Healthcare Services segment we are very
pleased to see that the United Family Hospital network has
continued to increase its profitability on a consolidated
basis this quarter based on revenue growth system-wide. 
Growth continues in both the Beijing and Shanghai markets
and we expect continued profitability from this division. 
We closed on a long-term financing package with the
International Finance Corporation of the World Bank for
approximately $8 million during the quarter which is now
providing us with capital funding for expansion projects
throughout the United Family Hospital network and which has
allowed us to restructure our balance sheet debt along more
traditional hospital ratios.  Our formal accreditation from
the Joint Commission International of the United Family
Hospital network operations in Beijing sets us distinctly
apart from any other healthcare network in Asia.  It is a
strong, global affirmation from the premier accreditation
agency in the health services industry of our quality
standard at United Family Hospitals.  This is the hallmark
of our brand value.  We are the first hospital network in
Asia to receive this accreditation. 

    "In the Medical Capital Equipment segment our
results included delivery of goods under the current phase
of our German KfW financing package which helped to offset
the continuation of several factors which are impacting our
results so far this year.  These include lacklustre sales in
certain product categories due to maturing product life
cycle issues, increased competition in certain mid-tier
product markets and delays due to product registrations in
other product categories.  We continue to focus on cost
containment and have new premium and mid-tier market
product releases scheduled during the fourth quarter.  In
addition, the product registration process has recently
been completed for another line of products that has
allowed sales to proceed.  We have experienced such down
periods in the capital equipment business before in China. 
We believe there is basically no change to the underlying
demand for the products and services we provide to the
Chinese hospital markets. 

    "On November 23, 2005, we announced that we would
close down operations of the retail pharmacy distribution
business, which comprises most of the operations of the
Healthcare Products Distribution segment.  The logistics
operations of the segment will migrate to the parent
company level and continue to provide services to other
business units of the Company.  During the recent quarter,
the business operations of the segment generally continued
to be routine as the closedown process began.  The
closedown process of the retail pharmacy business is
continuing at the time of this release.  Our objective is
to minimize the overall costs to the Company through the
careful migration of personnel where possible and
realization of assets.  Although we originally expected the
closedown to be substantially completed by December 31,
2005, managing the process in order to reduce associated
costs to us has extended the implementation timeline beyond
our original estimate by a few months." 

    About Chindex

    Chindex is an American healthcare company supplying
both medical equipment and healthcare services to the
Chinese marketplace, including Hong Kong.  It sells medical
equipment produced by a number of major multinational
companies including Siemens AG as its exclusive
distribution partner for the sales and servicing of color
doppler ultrasound systems.  It also arranges financing
packages for the supply of medical equipment to hospitals
in China utilizing the export loan and loan guarantee
programs of both the U.S. Export-Import Bank and the German
KfW Development Bank.  It provides healthcare services
through the operations of its network of private primary
care hospitals and affiliated ambulatory clinics in China. 
With twenty-four years of experience, approximately 1,000
employees, and operations in the United States, China and
Hong Kong, the Company's strategy is to expand its
cross-cultural reach by providing leading edge healthcare
technologies, quality products and services to Greater
China's professional communities.  Further company
information may be found at the Company's websites,
http://www.chindex.com and 
http://www.unitedfamilyhospitals.com .

    Some of the information in this press release may
contain statements regarding future expectations, plans,
prospects for performance of the Company that constitute
forward-looking statements for purposes of the safe harbor
provisions of The Private Securities Litigation Reform Act
of 1995.  The Company cannot guarantee future results,
levels of activity, performance or achievements.  The
numbers discussed in this press release also involve risks
and uncertainties.  The following factors, among others,
could cause actual results to differ materially from those
described by such statements: our ability to manage our
growth and maintain adequate controls, our ability to
obtain additional financing, the loss of services of key
personnel, general market conditions including inflation or
foreign currency fluctuations, our dependence on
relationships with suppliers, the timing of our revenues
and fluctuations in financial performance, the availability
to our customers of third-party financings, product
liability claims and product recalls, competition, hiring
and retaining qualified sales and service personnel,
management of inventory, relations with foreign trade
corporations, dependence on sub-distributors and dealers,
completion and opening of healthcare facilities, attracting
and retaining qualified physicians and other hospital
personnel, regulatory compliance, the cost of malpractice,
our dependence on our information systems, the economic
policies of the Chinese government, the newness and
undeveloped nature of the Chinese legal system, the
regulation of the conversion of Chinese currency, future
epidemics in China such as SARS or Avian Flu, the control
over our operation by insiders, continuity of relationships
and variability of financial margins with existing
suppliers, our liquidity and availability of capital
resources to meet cash requirements, including capital
expenditures, bid and performance bonds, limitations on the
inter-entity transfers and other limitations imposed by
existing credit facilities, uncertainty about the costs
related to the closedown of the Healthcare Products
Distribution segment, and those other factors contained in
the section titled "Risk Factors" as set forth in
the Company's Registration Statement (File No. 333-114996)
declared effective by the Securities and Exchange
Commission on December 5, 2005, as well as other documents
that may be filed by the Company from time to time with the
Securities and Exchange Commission.  The forward-looking
statements and numbers contained herein represent the
judgment of the Company, as of the date of this press
release, and the Company disclaims any intent or obligation
to update such forward-looking statements to reflect any
change in the Company's expectations with regard thereto or
any change in events, conditions, circumstances on which
such statements are based.


CHINDEX INTERNATIONAL, INC.
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(thousands except share and per share data)
(Unaudited)

                                    Three months ended     
Nine months ended
                                       December 31,        
   December 31,      
                                     2005        2004      
 2005        2004 
    Product sales                  $17,246     $17,141    
$51,510     $60,509 
    Healthcare services revenue      9,920       5,188     
26,289      16,050 
    Total revenue                   27,166      22,329     
77,799      76,559 
                                                           
             
    Cost and expenses                                      
             
     Product sales costs            13,784      13,587     
40,906      48,462 
     Healthcare services costs       9,151       6,751     
24,559      16,798 
     Selling and marketing                                 
             
      expenses                       3,018       3,297     
 9,347       8,962 
     General and                                           
             
      administrative expenses        1,729       2,039     
 5,743       5,190 
    Loss from operations              (516)     (3,345)    
(2,756)     (2,853)
    Other (expenses) and income                            
                                 
     Interest expense                 (203)        (36)    
  (397)       (108)
     Interest income                    50          33     
   117          66 
     Foreign exchange gain                                 
             
      (loss)                            48         (20)    
   379         (50)
     Miscellaneous (expense)                               
              
      income  - net                    (59)        (31)    
    23         (65)
    Loss before income taxes          (680)     (3,399)    
(2,634)     (3,010)
    Benefit from (provision                                
             
     for) income taxes                 217        (314)    
    90        (549)
    Net loss                         $(463)    $(3,713)   
$(2,544)    $(3,559)
    Net loss per common share -                            
             
     basic and diluted               $(.07)      $(.69)    
 $(.39)      $(.68)
                                                           
             
    Weighted average shares                                
             
     outstanding - basic and                               
              
     diluted                     6,536,122   5,405,337  
6,518,042   5,250,244 


CHINDEX INTERNATIONAL, INC.
CONSOLIDATED CONDENSED BALANCE SHEETS
(thousands except share data)
(Unaudited)

                                                    
December        March 31,    
                                                     31,
2005          2005      
                                     ASSETS                
                 
    Current assets:                                        
             
        Cash and cash equivalents                    
$7,683          $8,173 
        Trade accounts receivable, less                    
             
         allowance for doubtful accounts of                
              
         $2,458 and $1,851, respectively                   
                                 
              Equipment sales receivables            
11,491          13,120 
              Patient service receivables             
4,532           2,706 
        Inventories, net                             
10,755          10,856 
        Deferred income tax                             
341             222 
        Other current assets                          
2,722           2,034 
                  Total current assets               
37,524          37,111 
    Property and equipment, net                      
18,064          17,620 
    Long-term deferred income taxes                   
2,210           1,780 
    Other assets                                        
725             777 
                  Total assets                      
$58,523         $57,288 

                      LIABILITIES AND STOCKHOLDERS' EQUITY 
                
    Current liabilities:                                   
                 
        Accounts payable and accrued                       
             
         expenses                                   
$24,371         $26,420 
        Short-term portion of                              
            
         capitalized leases                              
82             189 
        Short-term debt and vendor                         
             
         financing                                    
2,413           2,839 
        Income taxes payable                            
177               4 
        Total current liabilities                    
27,043          29,452 
    Long-term portion of capitalized                       
            
     leases                                             
103             124 
    Long-term debt and vendor financing               
8,802           2,749 
        Total liabilities                            
35,948          32,325 
    Stockholders' equity:                                  
              
        Preferred stock, $.01 par                          
                
         value, 500,000 shares authorized, 
         none issued                                      
0               0
        Common stock, $.01 par value,                      
             
         13,600,000 shares authorized,                     
              
         including 1,600,000 designated                    
              
         Class B:                                          
              
             Common stock - 5,783,515 and                  
             
              5,728,443 shares issued and                  
             
              at December 31, 2005 and March 31,           
             
              2005, respectively                         
58              57
             Class B stock - 775,000 shares                
               
              issued and outstanding at 
              December 31, 2005 and 
              March 31, 2005                              
8               8
        Additional paid in capital                   
35,995          35,884 
        Accumulated other comprehensive                    
             
         income                                          
61              17 
        Accumulated deficit                         
(13,547)        (11,003)
        Total stockholders' equity                   
22,575          24,963 
        Total liabilities and                              
             
         stockholders' equity                       
$58,523         $57,288 


    SEGMENT INFORMATION

    The Company has three reportable segments: Medical
Capital Equipment, Healthcare Services and Healthcare
Products Distribution.  The Company evaluates performance
and allocates resources based on profit or loss from
operations before income taxes, not including gains or
losses on the Company's investment portfolio.  The
following segment information has been provided per
Statement of Financial Accounting Standards No. 131,
"Disclosures about Segments of an Enterprise and
Related Information:"


                              Medical                 
Healthcare           
                              Capital     Healthcare   
Products            
                             Equipment     Services  
Distribution     Total    
    As of December 31, 2005                                
             
    Assets                  $23,310,000  $26,244,000  
$8,969,000  $58,523,000 
    For the quarter ended
     December 31, 2005:
    Sales and service
     revenue                $10,143,000   $9,920,000  
$7,103,000  $27,166,000 
    Gross Profit              3,111,000          n/a     
351,000          n/a 
    Gross Profit %                   31 %        n/a       
    5 %        n/a 
    Income (loss) from                                     
             
     operations                 $15,000     $439,000   
$(970,000)   $(516,000)
    Other (expense) net                                    
          (164,000)
    Loss before income taxes                               
         $(680,000)


                              Medical                 
Healthcare           
                              Capital     Healthcare   
Products            
                             Equipment     Services  
Distribution    Total    
    As of March 31, 2005                                   
             
    Assets                 $22,698,000  $20,878,000 
$13,712,000  $57,288,000 
    For the quarter ended 
     December 31, 2004:                              
    Sales and service                                      
             
     revenue                $9,462,000   $5,188,000  
$7,679,000  $22,329,000 
    Gross Profit             2,520,000          n/a   
1,034,000          n/a 
    Gross Profit %                  27 %        n/a        
  13 %        n/a 
                                                           
  
    Loss from operations   $(1,035,000) $(1,838,000)  
$(472,000) $(3,345,000)
    Other (expense) net                                    
          (54,000)
    Loss before income taxes                               
      $(3,399,000)


                              Medical                 
Healthcare           
                              Capital     Healthcare   
Products            
                             Equipment     Services  
Distribution    Total    
    As of December 31, 2005                                
             
    Assets                 $23,310,000  $26,244,000   
$8,969,000  $58,523,000
    For the nine-months 
     ended December 31, 
     2005:                         
    Sales and service                                      
    
     revenue               $31,032,000  $26,289,000  
$20,478,000  $77,799,000 
    Gross Profit             9,222,000          n/a    
1,383,000          n/a 
    Gross Profit %                  30 %        n/a        
   7 %         n/a 
    (Loss) income from                                     
             
     operations             $(241,000)     $586,000 
$(3,101,000)  $(2,756,000)
    Other income net                                       
           122,000 
    Loss before income taxes                               
       $(2,634,000)


                              Medical                 
Healthcare           
                              Capital     Healthcare   
Products            
                             Equipment     Services  
Distribution    Total    
    As of March 31, 2005                                   
             
    Assets                  $22,698,000  $20,878,000 
$13,712,000  $57,288,000
    For the nine-months
     ended December 31, 
     2004:                          
    Sales and service                                      
    
     revenue                $34,393,000  $16,050,000 
$26,116,000  $76,559,000 
    Gross Profit              9,220,000          n/a   
2,826,000          n/a 
    Gross Profit %                   27 %        n/a       
   11 %        n/a 
    Income (loss) from                                     
             
     operations                 $90,000  $(1,446,000)
$(1,497,000) $(2,853,000)
    Other (expense) net                                    
          (157,000)
    Loss before income taxes                               
       $(3,010,000)


     For more information, please contact:

      Lawrence Pemble or Judy Zakreski
      Chindex International, Inc.
      Tel:  +1-30-215-7777

SOURCE  Chindex International, Inc.
2007'01.30.Tue

沖データ、小型・低価格・高速印字を実現したBRICs市場向けドットインパクトプリンターを発売

沖データ、BRICs市場向けドットインパクトプリンタの戦略商品を新発売

~RoHS対応の小型・低価格商品を世界に先駆け中国市場に投入~


 プリンティングソリューションの株式会社沖データ(社長:前野幹彦、本社:東京都港区)は、低価格でありながら高速印字と小型化を実現した、BRICs市場向けドットインパクトプリンタの新商品MICROLINE 1190の開発に成功しました。世界に先駆け今月より、成長を続ける中国市場に販売開始します。BRICs市場を主なターゲットとし、官公庁、金融機関、小売業などの企業ユーザに向けて、世界で2008年度20万台の販売を目指します。

 新商品は、官公庁、金融、教育、小売、医療、輸送、自動車など幅広い業界の用途に活躍する、低価格ドットインパクトプリンタです。同価格帯のドットインパクトプリンタでは初めて、USBインターフェイスの標準装備と最大333CPSの高速印字を実現しました。また、様々な使用場所に対応できるよう、従来製品と比較して設置面積、容積、重量の20%削減に成功し、クラス最小サイズの設置面積と筐体容積を実現しています。なお、本商品はRoHSにも対応した高い環境性能を備えています。

 世界のドットインパクトプリンタの市場は全体的には縮小傾向にあるものの、中国を中心としたアジア地域や中南米地域、東欧・中近東地域での低価格商品の需要が大きく、今後も堅調に推移すると予測されています。また、2006年度には380万台のドットインパクトプリンタ市場規模の中で、低価格商品市場は180万台あるとされており、新商品はこれらの市場の要求に応える機能と価格を備えています。

 弊社のドットインパクトプリンタは、2005年に米国、西欧、日本総計で金額シェア1位になるなど、世界中の業務用プリンタユーザの高い信頼と支持を得ています。一方、これまでは高機能商品に注力してきたため、低価格商品の需要の高いBRICs市場では、2位にとどまっています。(注)

 弊社では、BRICs市場特有の多様な要求に、きめ細かく応えることで、市場に最適化した商品をつくりあげることに成功しました。本商品は、世界最大のドットインパクトプリンタ市場である中国市場から販売を開始し、順次世界各地での展開を進めていきます。

(注)出典:IDC Worldwide Quarterly Hardcopy Peripherals Tracker, Q1 2006
 ドットインパクトプリンタ:IDC定義によるシリアルドットマトリックスプリンタ


【 新製品の主な仕様 】
 印字速度:最大333CPS
 複写枚数:1+4
 インターフェイス:セントロ、USB
 サイズ:349(W)×232(D)×150(H)


※MICROLINEは、株式会社沖データの商標です。
※OKI Printing Solutionsは、株式会社沖データのブランドです。
※その他、記載されている会社名、製品名は各社の商標または登録商標です。
※沖データ中国向けホームページ:http://www.okidata.com.cn/

2007'01.30.Tue

ソニー銀行、11月末まで住宅ローン金利優遇キャンペーンを実施

住宅ローン金利優遇キャンペーン実施のお知らせ


 ソニー銀行株式会社(代表取締役社長:石井 茂/本社:東京都港区/通称:ソニーバンク)は、11月30日(木)まで、ソニーバンク標準の住宅ローン金利から一律0.9%(年利)の金利を優遇する住宅ローン金利優遇キャンペーンを行いますのでお知らせいたします。

 キャンペーン期間中に仮審査お申し込みを受け付け、2007年3月30日(金)までにお借り入れの住宅ローンが対象となります。金利の優遇は、変動金利や固定金利〔2・3・5・7・10・15・20年、20年超(全期間)〕のすべての金利タイプについて、お借り入れ全期間に適用されます。金利タイプを変更された場合も、継続して優遇いたします。新規の住宅購入のほか、住宅ローンの借り換えにもご利用いただけます。

 ソニーバンクの住宅ローンは、来店不要、保証料不要、インターネットで繰り上げ返済や金利タイプの変更が容易に可能など、インターネットの特性を活かした利便性の高い商品となっています。さらに、変動金利に固定金利を組み合わせる機能(部分固定金利特約)のご利用も可能です。

 ソニーバンクは、お客さまの住宅資金ニーズに積極的にお応えするため、金利と利便性の両面から魅力のある住宅ローンを提供してまいります。


■住宅ローン金利優遇キャンペーンの概要

キャンペーン期間:2006年11月30日(木)まで
キャンペーン内容:キャンペーン期間中に仮審査お申し込みを受け付け、2007年3月30日(金)までにお借り入れの住宅ローン
キャンペーンの対象:住宅ローンのお借り入れ全期間、すべての金利タイプでソニーバンク標準の住宅ローン金利から一律0.9%(年利)を優遇

・キャンペーン期間中に、金融情勢等によっては本キャンペーンの優遇金利幅を変更する場合があります。
・すでにソニーバンクでお借り入れいただいている住宅ローンのお借り換えにはご利用いただけません。
・金融情勢等により、キャンペーン期間終了後も本キャンペーンのお取り扱いを継続する場合や、本キャンペーン内容を見直す場合があります。また今後予告なくお取り扱いを中止する場合があります。
・延滞が発生した場合は優遇を取り消し、金利を引き上げさせていただく場合があります。

以上


ソニーバンクのサイト
●企業サイト  http://sonybank.net/
●サービスサイト
  (インターネットバンキングサイト)  http://moneykit.net/
  (モバイルバンキングサイト)     http://mb.moneykit.net/

(c)Sony Bank Inc.  MONEYKit はソニー銀行株式会社の登録商標です。

お客さまからのお問い合わせ先
カスタマーセンター         0120-365-723(フリーダイヤル)
携帯電話・PHS・海外からは 03-6730-2700(通話料有料)
※番号をお間違えにならないようにくれぐれもご注意ください。
※IP電話をご利用の場合、ご入力内容が確認できないことがございます。
受け付け日:1月1日~3日および5月3日~5日を除く毎日
受け付け時間:
 平日       9:00~20:00
 土・日・祝日  9:00~17:00(12月31日9:00~17:00)



2007'01.30.Tue

明星食品、スープの旨みをアップしたカップめん「明星 中華そば いろは屋の塩」を発売

オーソドックス味覚で充実した品質、リーズナブルなカップ麺。深みのある旨味がアップして登場!
『明星 中華そば いろは屋の塩』
リニューアル発売


 明星食品株式会社(社長:永野博信)では、カップめんの『明星 中華そば いろは屋の塩』を、2006年 9月19日(火)から全国でリニューアル発売いたします。

 今回の商品は、"オーソドックス味覚で充実した品質、しかもリーズナブルなカップ麺"をコンセプトにしています。
 今回のリニューアルはスープを中心に行い、オホーツク産100%のほたて貝柱粉末を使用し、深みのある旨味がアップしました。

 商品の概要は次の通りです。


■商品の概要
 商  品  名:明星 中華そば いろは屋の塩
 内  容  量:94g(めん 70g)
 荷      姿:94g×12入=1ケース
 価      格:希望小売価格 155円(税抜き)
 JANコード  :4902881409551
 発売日及び発売地区:2006年9月19日(火)より、全国でリニューアル発売


■商品の特長

●め    ん:しなやかで歯切れのよさが特長の食べやすい中太麺です。(スーパーノンフライめん)

●ス ー プ:鶏がらをベースに野菜の旨みを加えた、やさしい風味の塩味スープ。粉末スープにオホーツク産100%のほたて貝柱粉末を使用し、コクと深みのある塩味に改良しました。

●か や く:食感が良く、ジューシーな角型のフリーズドライの焼豚、歯ごたえの良いメンマ、ねぎのかやくです。

●あとのせかやく:あざやかな彩りの白髪ねぎと粗挽き胡麻中心のスパイスミックスです。

●パッケージ:ネーミングの「いろは屋」には、基本、定番、初心、素朴などの意味あいを込め、まじめで誠実な中華そば屋の世界観を演出しています。暖簾をモチーフにした基本デザインを踏襲し、改良ポイントである"ホタテの旨み"をわかりやすくアピールできるようなラベル風のデザインにしました。


●読者のお問い合わせ先
 明星食品株式会社 お客様サービス室  03-3470-1311

[1056] [1057] [1058] [1059] [1060] [1061] [1062] [1063] [1064] [1065] [1066
«  BackHOME : Next »
広告
ブログ内検索
カウンター

忍者ブログ[PR]